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A B S T R A C T
Background
Sickle cell disease (SCD) is a group of inherited disorders of haemoglobin (Hb) structure in a person who has inherited two mutant globin
genes (one from each parent), at least one of which is always the sickle mutation. It is estimated that between 5% and 7% of the world's
population are carriers of the mutant Hb gene, and SCD is the most commonly inherited blood disorder.
SCD is characterized by distorted sickle-shaped red blood cells. Manifestations of the disease are attributed to either haemolysis
(premature red cell destruction) or vaso-occlusion (obstruction of blood flow, the most common manifestation). Shortened lifespans are
attributable to serious comorbidities associated with the disease, including renal failure, acute cholecystitis, pulmonary hypertension,
aplastic crisis, pulmonary embolus, stroke, acute chest syndrome, and sepsis.
Vaso-occlusion can lead to an acute, painful crisis (sickle cell crisis, vaso-occlusive crisis (VOC) or vaso-occlusive episode). Pain is most
oIen reported in the joints, extremities, back or chest, but it can occur anywhere and can last for several days or weeks. The bone and
muscle pain experienced during a sickle cell crisis is both acute and recurrent.
Key pharmacological treatments for VOC include opioid analgesics, non-opioid analgesics, and combinations of drugs. Non-
pharmacological approaches, such as relaxation, hypnosis, heat, ice and acupuncture, have been used in conjunction to rehydrating the
patient and reduce the sickling process.
Objectives
To assess the analgesic e#icacy and adverse events of pharmacological interventions to treat acute painful sickle cell vaso-occlusive crises
in adults, in any setting.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online, MEDLINE via Ovid,
Embase via Ovid and LILACS, from inception to September 2019. We also searched the reference lists of retrieved studies and reviews, and
searched online clinical trial registries.
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Selection criteria
Randomized, controlled, double-blind trials of pharmacological interventions, of any dose and by any route, compared to placebo or any
active comparator, for the treatment (not prevention) of painful sickle cell VOC in adults.
Data collection and analysis
Three review authors independently assessed studies for eligibility. We planned to use dichotomous data to calculate risk ratio (RR) and
number needed to treat for one additional event, using standard methods. Our primary outcomes were participant-reported pain relief of
50%, or 30%, or greater; Patient Global Impression of Change (PGIC) very much improved, or much or very much improved. Our secondary
outcomes included adverse events, serious adverse events, and withdrawals due to adverse events. We assessed GRADE and created three
'Summary of findings' tables.
Main results
We included nine studies with data for 638 VOC events and 594 participants aged 17 to 42 years with SCD presenting to a hospital emergency
department in a painful VOC. Three studies investigated a non-steroidal anti-inflammatory drug (NSAID) compared to placebo. One study
compared an opioid with a placebo, two studies compared an opioid with an active comparator, two studies compared an anticoagulant
with a placebo, and one study compared a combination of three drugs with a combination of four drugs.
Risk of bias across the nine studies varied. Studies were primarily at an unclear risk of selection, performance, and detection bias. Studies
were primarily at a high risk of bias for size with fewer than 50 participants per treatment arm; two studies had 50 to 199 participants per
treatment arm (unclear risk).
Non-steroidal anti-inflammatory drugs (NSAID) compared with placebo
No data were reported regarding participant-reported pain relief of 50% or 30% or greater.
The e#icacy was uncertain regarding PGIC very much improved, and PGIC much or very much improved (no di#erence; 1 study, 21
participants; very low-quality evidence).
Very low-quality, uncertain results suggested similar rates of adverse events across both the NSAIDs group (16/45 adverse events, 1/56
serious adverse events, and 1/56 withdrawal due to adverse events) and the placebo group (19/45 adverse events, 2/56 serious adverse
events, and 1/56 withdrawal due to adverse events).
Opioids compared with placebo
No data were reported regarding participant-reported pain relief of 50% or 30%, PGIC, or adverse events (any adverse event, serious
adverse events, and withdrawals due to adverse events).
Opioids compared with active comparator
No data were reported regarding participant-reported pain relief of 50% or 30% or greater.
The results were uncertain regarding PGIC very much improved (33% of the opioids group versus 19% of the placebo group). No data were
reported regarding PGIC much or very much improved.
Very low-quality, uncertain results suggested similar rates of adverse events across both the opioids group (9/66 adverse events, and
0/66 serious adverse events) and the placebo group (7/64 adverse events, 0/66 serious adverse events). No data were reported regarding
withdrawal due to adverse events.
Quality of the evidence
We downgraded the quality of the evidence by three levels to very low-quality because there are too few data to have confidence in results
(e.g. too few participants per treatment arm). Where no data were reported for an outcome, we had no evidence to support or refute
(quality of the evidence is unknown).
Authors' conclusions
This review identified only nine studies, with insu#icient data for all pharmacological interventions for analysis.
The available evidence is very uncertain regarding the e#icacy or harm from pharmacological interventions used to treat pain related to
sickle cell VOC in adults. This area could benefit most from more high quality, certain evidence, as well as the establishment of suitable
registries which record interventions and outcomes for this group of people.
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Medicines for treating painful sickle cell crises in adults
Bottom line
We are uncertain which medicines provide the best pain relief for adults experiencing a painful sickle cell crisis.
Background
People with sickle cell disease have abnormally shaped red cells in their blood. Sickle cell disease is the most common inherited blood
disorder around the world. It is estimated globally that 367 million to 500 million people are carriers. People with sickle cell disease have
a higher chance of life-threatening complications, such as infection, severe chest pain and stroke in early life, and kidney or liver damage
in adulthood.
A pain crisis is the most common problem of sickle cell disease and can require several treatments at once, usually in an emergency
situation. The first priority is to control the pain, using medicines (such as opioids, non-steroidal anti-inflammatories, paracetamol, and
blood thinners) or relaxation, hypnosis, heat, ice, or acupuncture.
Study characteristics
In September 2019, we searched for clinical trials that used medicines in any setting to treat painful sickle cell crises. We found nine trials,
with 594 adults (aged 17 to 42 years) who had sickle cell disease, experiencing a combined total of 638 painful episodes.
Key results
The studies looked at di#erent comparisons of the medicines butorphanol, cetiedil, fentanyl, ketoprofen, ketorolac, metoclopramide,
morphine, paracetamol, placebo, tinzaparin, and tramadol. Only three studies compared the same two drugs (non-steroidal anti-
inflammatory drugs such as ibuprofen, aspirin, or naproxen, with a placebo (pretend treatment)) and we had very limited data to be able
to investigate the e#ects on pain scores from these medicines.
Side e#ects were rare and were generally mild.
Quality of the evidence
We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low-quality evidence means that
we are very uncertain about the results. High-quality evidence means that we are very confident in the results. For pain relief and side
e#ects, we rated the quality of evidence as very low.
We downgraded the quality of the evidence to very low because there were not enough data (e.g. too few participants). For some outcomes
the quality of the evidence is unknown because there was no evidence available.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Non-steroidal anti-inflammatory drugs (NSAID) compared with placebo for painful sickle cell vaso-
occlusive crises
NSAIDs compared with placebo for painful sickle cell vaso-occlusive crises
Patient or population: adults with sickle cell disease in a vaso-occlusive crises
Settings: emergency departments
Intervention: NSAIDs (ketorolac or ketoprofen)
Comparison: placebo
Illustrative comparative
risks* (95% CI)
Outcomes
Placebo NSAIDs
Relative ef-
fect
(95% CI)
No of participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Participant-reported pain relief of
50% or greater
No data No data No data No data No dataa Quality of the
evidence is
unknown
Participant-reported pain relief of
30% or greater
No data No data No data No data No dataa Quality of the
evidence is
unknown
PGIC very much improved
(Follow-up: up to 5 days)
0/11 3/10 RR 7.64 (0.44
to 131.75)
21 participants, 21 VOC events (1
study)
⊕⊝⊝⊝
Very lowb
—
PGIC much or very much improved
(Follow-up: up to 5 days)
4/11 6/10 RR 1.65 (0.65
to 4.19)
21 participants, 21 VOC events (1
study)
⊕⊝⊝⊝
Very lowb
—
Any adverse event
(Follow-up: up to 5 days)
19/45 16/45 N/A 72 participants, 90 VOC events (2 stud-
ies)
⊕⊝⊝⊝
Very lowb
—
Serious adverse events
(Follow-up: up to 5 days)
2/56 1/55 N/A 93 participants, 111 VOC events (3
studies)
⊕⊝⊝⊝
Very lowb
—
Withdrawals due to adverse events 1/56 1/55 N/A 93 participants, 111 VOC events (3
studies)
⊕⊝⊝⊝
Very lowb
—
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(Follow-up: up to 5 days)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; N/A: not applicable; NSAID: non-steroidal anti-inflammatory drug; PGIC: Patient Global Impression of Change; RR: risk ratio; VOC: vaso-occlusive
crisis.
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substan-
tially different.
Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
a No data available, therefore no GRADE rating has been performed for this outcome and the quality of the evidence is unknown.
b Downgraded three levels; too few data (limited number of participants per treatment arm) to have confidence in results.
 
 
Summary of findings 2.   Opioids compared with placebo for painful sickle cell vaso-occlusive crises
Opioids compared with placebo for painful sickle cell vaso-occlusive crises
Patient or population: adults with sickle cell disease in a vaso-occlusive crisis
Settings: emergency departments
Intervention: opioids
Comparison: placebo
Illustrative comparative
risks* (95% CI)
Outcomes
Placebo Opioids
Relative ef-
fect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Participant-reported pain relief of 50% or
greater
No data No data N/A N/A No dataa Quality of the evidence is un-
known
Participant-reported pain relief of 30% or
greater
No data No data N/A N/A No dataa Quality of the evidence is un-
known
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PGIC very much improved No data No data N/A N/A No dataa Quality of the evidence is un-
known
PGIC much or very much improved No data No data N/A N/A No dataa Quality of the evidence is un-
known
Any adverse event No data No data N/A N/A No dataa Quality of the evidence is un-
known
Serious adverse event No data No data N/A N/A No dataa Quality of the evidence is un-
known
Withdrawals due to adverse events No data No data N/A N/A No dataa Quality of the evidence is un-
known
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; N/A: not applicable; PGIC: Patient Global Impression of Change; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect;
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substan-
tially different;
Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
a No data available, therefore no GRADE rating has been performed for this outcome and the quality of the evidence is unknown.
 
 
Summary of findings 3.   Opioids compared with active comparator for painful sickle cell vaso-occlusive crises
Opioids compared with active comparator for painful sickle cell vaso-occlusive crises
Patient or population: adults with sickle cell disease in a vaso-occlusive crisis
Settings: emergency departments
Intervention: opioids (morphine)
Comparison: active comparator (butorphanol or paracetamol)
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Illustrative comparative
risks* (95% CI)
Outcomes
Active com-
parator
Opioids
Relative ef-
fect
(95% CI)
No of participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Participant-reported pain relief of
50% or greater
No data No data N/A N/A No dataa Quality of the evidence
is unknown
Participant-reported pain relief of
30% or greater
No data No data N/A N/A No dataa Quality of the evidence
is unknown
PGIC very much improved
(Follow-up: within 1 day)
19.1 per 100 33.3 per 100 N/A 18 participants, 24 VOC
events (1 study)
⊕⊝⊝⊝
Very lowb
—
PGIC much or very much improved No data No data N/A N/A No dataa Quality of the evidence
is unknown
Any adverse event
(Follow-up: within 1 day)
7/64 9/66 N/A 124 participants, 130 VOC
events (2 studies)
⊕⊝⊝⊝
Very lowb
—
Serious adverse event
(Follow-up: within 1 day)
0/64 0/66 N/A 124 participants, 130 VOC
events (2 studies)
⊕⊝⊝⊝
Very lowb
—
Withdrawals due to adverse events No data No data N/A N/A No dataa Quality of the evidence
is unknown
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; N/A: not applicable; PGIC: Patient Global Impression of Change; RR: risk ratio; VOC: vaso-occlusive crisis.
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect;
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substan-
tially different;
Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
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a No data available, therefore no GRADE rating has been performed for this outcome and the quality of the evidence is unknown.
b Downgraded three levels; too few data (limited number of participants per treatment arm) to have confidence in results.
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B A C K G R O U N D
A previous review, entitled 'Pain management for sickle cell disease
in children and adults' was withdrawn as it was out of date
(Dunlop 2014). This is a completely new review focusing only on
the treatment of painful vaso-occlusive crises (VOC; or episodes) of
sickle cell disease and it excludes the paediatric population.
Description of the condition
Sickle cell disease is a generic term for a group of inherited
disorders of haemoglobin (Hb) structure in which the a#ected
person inherits two mutant globin genes (one from each parent),
at least one of which is always the sickle mutation (WHO 2010).
The latter results from a single nucleotide change (GAT→GTT) in
the sixth codon of exon 1 of the β-globin gene responsible for the
synthesis of the β-globin chain. The resulting replacement of the
normal glutamic acid by valine at position 6 in the β chain leads
to the formation of sickle Hb (Hb S). Sickle cell anaemia is the
homozygous state, in which the sickle gene is inherited from both
parents. Other sickle cell syndromes result from the coinheritance
of the sickle gene and a non-sickle gene, such as in Hb C, Hb OArab,
Hb D, β+-thalassaemia or β0-thalassemia (NIH 2014).
JB Herrick first described the abnormally shaped red blood cell
in 1910 (Herrick 1910). Sickle cell originated in Sub-Saharan Africa
and the Indian subcontinent (Martí-Carvajal 2009; Stuart 2004;
Weatherall 2006), and has persisted as a recessive trait due to the
survival advantage against malaria experienced by people with the
heterozygote form (Weatherall 2001). In recent years, the United
Nations and the World Health Organization have recognized sickle
cell disease as a global public health problem due to population
mobility, with increased migration from high- to low-frequency
sickle Hb areas (WHO 2010). Combined with the global increase in
population size, reduction in child mortality and improved adult
survival, the worldwide burden of sickle cell disease is predicted to
increase (Al Hajeri 2007; Martí-Carvajal 2009; Piel 2013).
Sickle cell disease is the most common inherited blood
disorder globally. Epidemiologically, it is estimated that between
5% (approximately 367 million people) (WHO 2011) and 7%
(approximately 500 million people) (Weatherall 2001) of the world's
population are carriers of the mutant Hb gene.
Worldwide, the African region has the highest prevalence with an
estimated 200,000 babies born with sickle cell disease every year
(Diallo 2002). In 2010, approximately 75% of the globally estimated
homozygous sickle cell disease newborns were from Sub-Saharan
Africa (Piel 2013). In the US, the number of people living with sickle
cell disease is approximately 100,000 and it predominantly a#ects
Americans of African descent (NIH 2015). In addition to this, 3.5
million African-Americans have the sickle cell trait HbAS genotype
(i.e. are heterozygote carriers of sickle Hb) (Yawn 2014). The UK
reports an estimated prevalence of 12,500 people with the disease
(National Screening Committee 2006).
Shortened lifespans are attributable to serious comorbidities
associated with the disease. People with sickle cell disease have
a higher chance of life-threatening complications, such as sepsis,
acute chest syndrome and stroke in early life, and end organ
damage in adulthood.(Tanabe 2012). For example, in the 1990s,
African-Americans with sickle cell disease had a life expectancy of
less than 50 years, compared with the life expectancy of African-
Americans without sickle cell disease of more than 70 years (Platt
1994).
Sickle cell disease is characterized by the presence of distorted
sickle-shaped red blood cells in the bloodstream. These sickle-
shaped cells arise as a result of the "polymerization (gelling
of the molecules) of the abnormal Hb in the red blood cells
when they release their combined oxygen" (Al Hajeri 2007). Many
manifestations of the disease are attributed to either haemolysis
(premature red cell destruction) or vaso-occlusion (obstruction
of blood flow), which is the most common manifestation (Al
Hajeri 2007). Red cell dehydration contributes to vaso-occlusion:
dehydrated red cells adhere to vascular endothelium, which results
in blockage of blood flow (Lutz 2015). Other severe outcomes of
the manifestations of sickle cell disease can include acute chest
syndrome (chest crisis), priapism, acute cholecystitis, acute stroke
and aplastic crisis (NIH 2014).
Vaso-occlusion can lead to acute, painful crisis. This is also known
as a sickle cell crisis, VOC or vaso-occlusive episode. Pain is most
oIen reported in the joints, extremities, back or chest, but it
can occur anywhere and can last for several days or weeks. The
frequency and severity of the painful episodes vary widely within
and between individuals. The peak incidence is in late adolescence
and early adulthood (Ballas 2007). The bone and muscle pain
experienced during a sickle cell crisis is both acute (sudden onset
of severe intensity) and recurrent (reoccurring unpredictably and
intermittently over long periods while fluctuating in frequency and
quality) (Serjeant 1994; Thienhaus 2002).
This review focused on the vaso-occlusive manifestation of the
disease, which causes the acute and painful crises (episodes), VOC.
It excluded the other possible outcomes in people with sickle cell
disease.
Description of the intervention
A VOC can require several interventions, depending on the
person and situation. Treatment is primarily symptomatic and
aims to stabilize pain. As well as pharmacological agents, non-
pharmacological approaches, such as relaxation, hypnosis, heat,
ice and acupuncture, have been used to rehydrate the person and
reduce the sickling process (Ballas 2005; Ballas 2007; De Ceulaer
1982; Gaston 1986; Lane 2001; Okomo 2015).
In this review, we assessed pharmacological interventions used to
treat VOC in adults living with sickle cell disease. These included
(but were not limited to) opioid and non-opioid analgesics, as well
as partial agonists, mixed agonists–antagonists, antagonists and
adjuvants (Ballas 2007).
In context, a VOC is the hallmark of sickle cell disease and is
the most common cause of hospitalization (up to 90%) (Ballas
2005; Dampier 2013). Therefore, treatment for adults with VOC
is usually on presentation to an emergency healthcare facility,
requiring immediate treatment for acute and debilitating pain. In
addition, some people with sickle cell disease oIen self medicate
at home with pharmacological agents. In both settings, primary
management should focus on rapid pain control, whereby fluids
and analgesics should be administered immediately (Gillis 2012).
VOC can be treated with various drugs (described below). As with
all pharmacotherapies, the risk of adverse e#ects can be minimized
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by prescribing the lowest dose for the shortest duration possible to
control the symptoms (NICE 2015).
For all analgesia, the person's respiratory rate, pain and sedation
are assessed at 20-minute intervals until pain control is reached,
then monitored with analgesia readministered every four hours
(NICE 2015; Rees 2003). Patient-controlled administration (PCA) is
an option used in adolescents transitioning into adult care (Telfer
2014).
Opioid analgesics
Opioid analgesics are recommended as the primary choice of pain
relief in VOC management (NICE 2015). They include (but are
not limited to): codeine, hydrocodone/paracetamol (hydrocodone/
acetaminophen), hydrocodone/ibuprofen, oxycodone (and with
codeine), morphine, hydromorphone, oxymorphone, methadone,
diamorphine and fentanyl (Ballas 2007). Opioids are generally
available in healthcare settings in most Western countries and are
oIen delivered as intravenous (IV) morphine every four to six hours.
In addition, oral opioids are prescribed as PCA aIer a VOC episode
(NICE 2015).
Most analgesic opioids have a half-life of two to four hours, with
the exception of methadone, propoxyphene and meperidine, for
which this can be one to several days (Trescot 2008). Although the
standard dosing is generally every four to six hours, some people
develop tolerance to opioids, thus requiring doses every two hours
(Okpala 2002). Combination with diclofenac or paracetamol (which
have di#erent mechanisms of action) helps keep opioid use to a
minimum (Okpala 2002).
The adverse e#ects of analgesic opioids include: (short-term)
respiratory depression, constipation, vomiting, nausea, pruritus
and hives (Ballas 2007), addiction, and withdrawals (Rosenblum
2008).
Non-opioid analgesics
Non-opioid analgesics are the other drugs of choice for managing a
VOC (NICE 2015). These include: paracetamol, non-selective cyclo-
oxygenase (COX) inhibitors (aspirin (acetylsalicylic acid), ibuprofen,
naproxen and ketorolac) and selective COX-2 inhibitors (celecoxib)
(Ballas 2007).
The most commonly used drugs from this family are non-steroidal
anti-inflammatory drugs (NSAIDs), paracetamol, diclofenac and
ketorolac. They are commonly used for mild-to-moderate pain
either alone or in combination with opioid analgesia (Rees 2003).
NSAIDs are available in most countries. The adverse e#ects of
NSAIDs include gastrointestinal complications and they should be
administered with caution in people with a history of renal failure,
bleeding tendencies, asthma or peptic ulcers (Rees 2003).
Paracetamol is also widely available in Western countries and is
administered orally at a dosage of 200 mg to 500 mg every four to six
hours until satisfactory pain relief has been achieved. The adverse
e#ects of paracetamol are influenced by the dosage and duration
of use and can include liver failure (Rees 2003).
Other pharmacotherapeutic drugs
Other pharmacotherapeutic drugs to be considered for analysis
in this review include partial agonists (e.g. buprenorphine
and buprenorphine/naloxone), mixed agonist-antagonists (e.g.
pentazocine, nalbuphine and butorphanol) and hydroxyurea
(Ballas 2007). Finally, we will also consider any other
pharmacotherapeutic drugs that we find, which are used to treat
VOC.
How the intervention might work
Analgesics work in several ways to treat VOC, thus the key factor
is whether the drugs provide relief of participant-reported pain.
Therefore, we were interested in gathering a comprehensive list of
all pharmacotherapeutic treatments that have been trialled in a
clinical setting to treat a new or recurrent painful crisis in people
with sickle cell disease. We were also interested in combination
drug therapies.
Why it is important to do this review
Globally, sickle cell disease is one of the four most common
autosomal-recessive disorders, along with thalassaemia, Tay-
Sachs disease and cystic fibrosis (Hussein 2015). In many countries,
there has been an improvement in the survival rate of children
with sickle cell disease who now live on into adulthood, thus
increasing the adult population living with this condition (Quinn
2010; Sasongko 2013).
We are unaware of any recent or up-to-date systematic reviews
that draw on comparisons of a full range of pharmacotherapies
used specifically to treat VOC in adults. Therefore, this review aimed
to address and analyse all available pharmacotherapies, including
drug combinations.
This systematic review also addressed the issue of tolerance or
habituation to opioids where this was reported in people with sickle
cell disease (Tanabe 2012; Waldrop 1995). Regular analgesia should
be given for acute pain when presenting in the emergency setting.
Due to people developing a tolerance and requiring more frequent
doses of opioids, it has been suggested that e#orts should be made
to prevent such tolerance developing in new patients because there
is a limited choice of injectable opioids that can be used in acute
painful episodes (Okpala 2002).
A systematic review of the current evidence on the reported
benefits and harms is required to clarify the most e#ective
pharmacotherapeutic options (and combinations) for e#ective
pain relief interventions in adults with acute painful sickle cell VOC.
O B J E C T I V E S
To assess the analgesic e#icacy and adverse events of
pharmacological interventions to treat acute painful sickle cell
vaso-occlusive crises in adults, in any setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs) with double-
blind assessment of participant outcomes following immediate
treatment for acute painful sickle cell vaso-occlusive episodes.
We considered studies of parallel and crossover trial designs. We
required full journal publication, with the exception of online
clinical trial results, summaries of otherwise unpublished clinical
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trials and extended abstracts of otherwise unpublished clinical
trials if su#icient data could be analysed. We excluded studies that
were non-randomized, case reports and clinical observations.
Types of participants
Studies included adults, aged 18 years and above, diagnosed with
sickle cell disease and who had an acute painful sickle cell VOC (new
or recurring).
We anticipated that some studies would contain some participants
below 18 years of age (such as adolescents mixed with adults over
18 years of age). In the protocol, we planned to extract the data
on participants aged 18 years and above and to contact the study
authors for the separate adult data if necessary. At review stage,
we changed this approach to include the study and data on all its
participants if less than 20% of the participants were aged 17 or
under. If greater than 20% of the participants were aged 17 years or
under, we planned to extract the data on the participants aged 18
years and above, and contact the authors of the studies for separate
adult data if necessary, However, this did not occur.
Types of interventions
Any pharmacological intervention at any dose, by any route,
administered for the relief of acute pain associated with a sickle cell
vaso-occlusive episode or event (new or recurring) and compared
to placebo or any active comparator.
We included studies treating the crisis in any healthcare setting, as
well as combination drug regimens. IN fluid replacement therapy
is a primary step in both the National Institute of Health and
Care Excellence (NICE) and National Institutes of Health (NIH)
guidelines for managing a sickle cell crisis (NICE 2015; NIH 2014),
and was, therefore, considered standard practice and not an active
comparator for the purpose of this review. We excluded studies
using agents to treat pain resulting from other causes and studies
using agents to attempt to treat the cause of sickle cell disease,
chronic pain or non-painful symptoms of the disease.
Types of outcome measures
Studies had to report pain assessment as either a primary or
secondary outcome to be eligible for this review.
We anticipated that studies would use a variety of outcome
measures, with the majority of studies using standard subjective
scales (numerical rating scale (NRS) or visual analogue scale (VAS))
for pain intensity or pain relief, or both (Dworkin 2008).
We used the following dichotomous measures of pain: at least 50%
pain relief over baseline (substantial), at least 30% pain relief over
baseline (moderate), very much improved on the Patient Global
Impression of Change (PGIC) (substantial), and much or very much
improved on the PGIC (moderate). These outcomes are di#erent
from those used in most earlier reviews (Wi#en 2005), and we
recognize that continuous responses to chronic pain generally do
not follow a normal (Gaussian) distribution. People with chronic
pain desire high levels of pain relief, ideally more than 50% and
ideally leading to no more than mild pain (Moore 2013; O'Brien
2010). For the purpose of this review, we considered it appropriate
to adapt these measurements of chronic pain to acute painful
episodes, as the outcomes used to measure the end points of
chronic pain are the same outcomes used to measure end points of
acute pain.
We included three 'Summary of findings' tables. The 'Summary
of findings' tables included outcomes of at least 50% and at least
30% pain intensity reduction, PGIC, serious adverse events (which
included death) and withdrawals due to adverse events. We used
the GRADE approach to assess the quality of the evidence related
to each of the key outcomes listed in here (Higgins 2011a), as
appropriate (see Data synthesis).
Primary outcomes
• Participant-reported pain relief of 50% or greater at 6, 12, 24, 48
hours and at the end of treatment.
• Participant-reported pain relief of 30% or greater at 6, 12, 24, 48
hours and at the end of treatment.
• Patient global impression of change (PGIC) very much improved.
• Patient global impression of change (PGIC) much or very much
improved.
Secondary outcomes
• Opioid consumption.
• Time to pain resolution.
• Length of hospitalization.
• Participants experiencing any adverse or serious adverse event.
Serious adverse events typically include any untoward medical
occurrence or e#ect that at any dose resulted in death, was life-
threatening, required hospitalization or prolongation of existing
hospitalization, resulted in persistent or significant disability
or incapacity, was a congenital anomaly or birth defect, was
an 'important medical event' that may have jeopardized the
person, or may have required an intervention to prevent one
of the above characteristics or consequences. Acute chest
syndrome is well documented as a reported adverse event of
VOC and we planned to assess the issues around tolerability of
the drugs.
• Any pain-related outcome indicating some improvement, such
as sleep quality or activities of daily living.
• Withdrawals due to lack of e#icacy, adverse events and for any
cause.
• Reports of tolerance or habituation to opioids.
Search methods for identification of studies
The Information Specialist carried out the searches.
Electronic searches
We searched the following databases without language
restrictions:
• Cochrane Central Register of Controlled Trials (CENTRAL; via the
Cochrane Library) searched 16 September 2019;
• MEDLINE and MEDLINE in Process (via Ovid) searched 1947 to 16
September 2019;
• Embase (via Ovid) searched 1974 to 2019 week 38;
• LILACS (via BIRME) searched 1982 to September 2019.
We used MeSH or equivalent and text-word terms. We tailored the
searches to the individual databases.
The search strategies for CENTRAL, MEDLINE, Embase and LILACS
are in Appendix 1.
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Searching other resources
We searched the metaRegister of controlled trials (mRCT)
(www.isrctn.com/), ClinicalTrials.gov (www.clinicaltrials.gov), and
the World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (apps.who.int/trialsearch/) for ongoing
trials. We also checked the reference lists of reviews and retrieved
articles for additional studies and performed citation searches on
key articles.
Data collection and analysis
Selection of studies
Three review authors (TC SB, and BJ) independently determined
the eligibility of each study identified by the search by reading
the title and abstract. The review authors then independently
eliminated studies that clearly did not satisfy the inclusion criteria
and obtained full copies of the remaining studies.
Three review authors (TC SB, and BJ) independently read these
reports to select relevant studies. In the event of disagreement,
a fourth review author (PW) adjudicated. We did not anonymize
the studies before assessment. We included a PRISMA flow chart,
which shows the status of identified studies (Moher 2009), as
recommended in Part 2 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011a). We included studies in
the review irrespective of whether measured outcome data were
reported in a 'usable' way.
Data extraction and management
Two review authors (TC and IH) independently extracted data using
a standard piloted form, and checked for agreement before entry
into Review Manager 5 (Review Manager 2014).
We included information about the pain condition, number of
participants treated, drug and dosing regimen, study design
(placebo or active control), study duration and follow-up, analgesic
outcome measures and results, withdrawals and adverse events
(participants experiencing any adverse event or serious adverse
event).
We collated multiple reports of the same study, so that each study,
rather than each report, was the unit of interest in the review.
We collected characteristics of the studies in su#icient detail to
complete the Characteristics of included studies table.
Assessment of risk of bias in included studies
Two review authors (TC and IH) independently assessed the
risk of bias for each study, using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011b), adapted from those used by the Cochrane Pregnancy and
Childbirth Group, with any disagreements resolved by discussion.
We completed a 'Risk of bias' table for each included study using
the 'Risk of bias' tool in Review Manager 5 (Review Manager 2014).
We assessed the following for each study.
• Random sequence generation (checking for possible selection
bias). We assessed the method used to generate the allocation
sequence as: low risk of bias (any truly random process, e.g.
random number table; computer random number generator);
unclear risk of bias (method used to generate sequence not
clearly stated). We excluded studies using a non-random process
(e.g. odd or even date of birth; hospital or clinic record number).
• Allocation concealment (checking for possible selection bias).
The method used to conceal allocation to interventions prior to
assignment determines whether intervention allocation could
have been foreseen in advance of, or during, recruitment or
changed aIer assignment. We assessed the methods as: low risk
of bias (e.g. telephone or central randomization; consecutively
numbered, sealed, opaque envelopes); unclear risk of bias
(method not clearly stated). We excluded studies that did not
conceal allocation (e.g. open list).
• Blinding of participants and personnel (checking for possible
performance bias). We assessed the methods used to blind
the participants and personnel from knowledge of which
intervention a participant received. We assessed the methods
as: low risk of bias (study stated that the participants and
personnel involved were blinded to treatment groups); unclear
risk of bias (study did not state whether or not participants and
personnel were blinded to treatment groups); or high risk of
bias (participants or personnel were not blinded) (as stated in
Types of studies, we included trials with or without blinding, and
participant- or observer-reported outcomes).
• Blinding of outcome assessment (checking for possible
detection bias). We assessed the methods used to blind
outcome assessors from knowledge of which intervention a
participant received. We assessed the methods as: low risk of
bias (study stated that it was blinded and described the method
used to achieve blinding, e.g. identical tablets; matched in
appearance and smell); unclear risk of bias (study stated that
it was blinded but did not provide an adequate description of
how it was achieved). We excluded studies that were not double-
blind.
• Incomplete outcome data (checking for possible attrition bias
due to the amount, nature and handling of incomplete outcome
data). We assessed the methods used to deal with incomplete
data as: low risk of bias (less than 10% of participants did
not complete the study or used 'baseline observation carried
forward' analysis, or both); unclear risk of bias (used 'last
observation carried forward' analysis); high risk of bias (used
'completer' analysis).
• Selective reporting (checking for possible reporting bias). We
assessed the methods used to report the outcomes of the
study as: low risk of bias (if all planned outcomes in the
protocol or methods were reported in the results); unclear
risk of bias (if there was no clear distinction between planned
outcomes and reported outcomes); or high risk of bias (if some
planned outcomes from the protocol or methods were clearly
not reported in the results).
• Size of study (checking for possible biases confounded by small-
study size). We assessed studies as being at low risk of bias (200
participants or more per treatment arm); unclear risk of bias (50
to 199 participants per treatment arm); high risk of bias (fewer
than 50 participants per treatment arm).
• Other bias, such as multiple publications, financial declarations,
participants with conflicts of interest. We assessed studies for
any additional sources of bias as low, unclear or high risk of bias,
and provided rationales.
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Measures of treatment e=ect
We used dichotomous data to calculate risk ratios (RR) with
95% confidence intervals (CI) using a fixed-e#ect model unless
there was significant statistical heterogeneity (see Assessment of
heterogeneity).
We calculated numbers needed to treat for an additional beneficial
outcome (NNTB) as the reciprocal of the absolute risk reduction
(ARR; McQuay 1998). For unwanted e#ects, the NNTB becomes the
number needed to treat for an additional harmful outcome (NNTH)
and is calculated in the same manner. We planned to use the term
number needed to treat to prevent an additional outcome (NNTp)
where the unwanted e#ect is less common with treatment than
control.
For our primary outcomes measuring pain, we planned not to
use continuous data in analyses because it is inappropriate where
there is underlying skewed distribution, as is usually the case
with analgesic response. For our secondary outcomes, we used
continuous data for the meta-analysis where appropriate.
Unit of analysis issues
We expected that the unit of analysis would be at the participant
level, with each participant providing one pain episode per trial. It
was possible that a trial may have included multiple pain events per
participant, introducing a statistical clustering e#ect with two pain
events in the same participant likely to be more similar than two
independent pain events from two di#erent participants; however,
this did not occur in any of our included studies. We had planned
to use the number of trial clusters and an estimate of the intraclass
correlation coe#icient to inflate the standard errors associated with
each clustered trial in this scenario.
We had planned for the unit of analysis to be each participant
from the first phase of treatment before crossing over (who, where
randomised, took at least one dose of study, and provided at least
one outcome score) if any included studies were crossover studies.
We would include the second phase of treatment if there was a
su#icient washout period and results were reported clearly and
separately. If not, and the results appeared unclear from which
phase they were taken, we would contact the authors and attempt
to gain access to the original data. Otherwise, we would not use the
data.
Dealing with missing data
We used intention-to-treat analysis where the intention-to-treat
population consisted of participants who were randomized,
received at least one dose of the assigned study treatment and
provided at least one post-baseline assessment. We assigned
missing participants zero improvement wherever possible.
Assessment of heterogeneity
We dealt with clinical heterogeneity (variation in participants,
interventions or outcomes) by combining studies that examined
similar conditions when possible. We assessed statistical
heterogeneity visually (L'Abbé 1987), and with the I2 statistic. We
considered the possible reasons when the I2 value was greater than
50%.
Assessment of reporting biases
The aim of this review was to use dichotomous outcomes of
known utility and of value to patients (Ho#man 2010; Moore
2010a; Moore 2010b; Moore 2010c; Moore 2013). The review did
not depend on what the authors of the original studies chose to
report or not, though di#iculties arose in studies failing to report
any dichotomous results. We extracted and used continuous data
where possible, which poorly reflected e#icacy and utility but was
useful for illustrative purposes only.
We assessed publication bias using a method designed to detect
the amount of unpublished data with a null e#ect required to make
any result clinically irrelevant (usually taken to mean an NNTB of 10
or higher; Moore 2008).
Data synthesis
We planned to meta-analyse data from similar comparisons using
a fixed-e#ect model in Review Manager 5 (Review Manager 2014).
Due to the lack of available data, we used Review Manager 5 to
undertake a summary of e#ects from individual studies, fixed-
e#ects and without group totals (Analysis 1.1; Analysis 1.2; Analysis
1.3; Analysis 1.4).
We planned to have used a random-e#ects model for meta-analysis
if there was significant clinical heterogeneity and it was considered
appropriate to combine studies. This did not occur.
Quality of the evidence
Two review authors (TC, PW) independently rated the quality of
the evidence for each outcome. We used the GRADE system to
rank the quality of the evidence using the GRADEprofiler Guideline
Development Tool soIware (GRADEpro GDT), and the guidelines
provided in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011a).
The GRADE approach uses five considerations (study limitations,
consistency of e#ect, imprecision, indirectness and publication
bias) to assess the quality of the body of evidence for each outcome.
The GRADE system uses the following criteria for assigning the
grade of evidence.
• High: further research is very unlikely to change our confidence
in the estimate of e#ect.
• Moderate: further research is likely to have an important impact
on our confidence in the estimate of e#ect and may change the
estimate.
• Low: further research is very likely to have an important impact
on our confidence in the estimate of e#ect and is likely to change
the estimate.
• Very low: any estimate of e#ect is very uncertain.
Reasons for decreasing grade are due to:
• serious (–1) or very serious (–2) limitation to study quality;
• important inconsistency (–1);
• some (–1) or major (–2) uncertainty about directness;
• imprecise or sparse data (–1);
• high probability of reporting bias (–1).
In addition, we anticipated there may have been circumstances
where the overall rating for a particular outcome would need to
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be adjusted per GRADE guidelines (Guyatt 2013a; Guyatt 2013b).
For example, if there were so few data that the results are highly
susceptible to the random play of chance, or if studies used last
observation carried forward imputation in circumstances where
there were substantial di#erences in adverse event withdrawals,
or where there were a small number of participants per treatment
arm, one would have no confidence in the result, and would need
to downgrade the quality of the evidence by three levels to very low
quality.
In circumstances where no data were reported for an outcome, the
quality of the evidence is unknown and we reported this as 'no
evidence to support or refute'.
Subgroup analysis and investigation of heterogeneity
We planned no subgroup analyses since experience from previous
reviews suggests a limited chance of su#icient data. We would have
considered subgroup classification between genotypes should
the data be available; however, the available data proved to be
insu#icient for this purpose.
Sensitivity analysis
We planned no sensitivity analysis because the evidence base is
known to be too small to allow reliable analysis. We did not plan to
pool results from sickle cell pain of di#erent origins in the primary
analyses.
R E S U L T S
Description of studies
Results of the search
A PRISMA flow diagram of the search results is shown in Figure 1.
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
 
The three main database searches found 848 records, of which we
removed 185 duplicates. We also searched clinicaltrials.gov and
app.who.int/trialsearch/ and found no additional eligible studies.
We screened the remaining 663 titles and abstracts for eligibility, of
which we removed 621 as clearly irrelevant studies.
We retrieved the full-text reports of the 42 remaining studies.
Twenty-seven were ineligible and excluded (Characteristics of
excluded studies table). Three studies are awaiting classification
(Characteristics of studies awaiting classification table), and three
studies are ongoing (Characteristics of ongoing studies table).
Nine studies fulfilled the eligibility criteria, which we included in
the qualitative synthesis. We entered three of these studies into a
quantitative analysis.
Included studies
We included nine studies in this review. See Characteristics of
included studies table.
Design
All nine studies were randomized double-blind placebo-controlled
trials with two arms. Eight studies were parallel groups and one
study had crossover arms.
Sample sizes
The sample sizes of the studies ranged from 18 participants
(Gonzalez 1988; Wright 1992) to 253 participants (Qari 2007).
Setting
Two studies were multicentre studies and seven were single-
centre studies. All studies were based in emergency departments of
hospitals from France, Italy, Saudi Arabia, and the USA. No included
studies were based in home or other settings.
Participants
The age ranges were adults from 17 to 42 years old. Gender ratios
were roughly equal between women and men across all studies. All
nine studies had inclusion criteria of pre-existing diagnosis of sickle
cell disease and presenting to the emergency department in a VOC.
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Interventions
Analgesic interventions varied including butorphanol, cetiedil,
fentanyl, hydromorphone, ketamine, ketoprofen, metoclopramide,
morphine, paracetamol, tinzaparin and tramadol.
Six studies administered IV bolus injections (Arambasik 2013;
Benjamin 1986; Gonzalez 1988; Qari 2007; Rehmani 2013; Wright
1992), three administered IV infusions (Bartolucci 2009; De
Franceschi 2016) and one administered an IV bolus followed by
an IV infusion (Perlin 1994). Two studies were a single dose of the
drug only and seven administered multiple doses of the treatments
(Rehmani 2013; Wright 1992).
Outcomes
All nine studies reported pain outcomes using a validated pain
scale or global assessment scores. Four studies reported opioid
consumption (Bartolucci 2009; Perlin 1994; Rehmani 2013; Wright
1992). Two studies reported time to pain resolution (Bartolucci
2009; Qari 2007). Two studies reported the duration of time spent
in hospital (Perlin 1994; Qari 2007). All but two studies reported
adverse events and withdrawals (Arambasik 2013; Qari 2007).
Excluded studies
We excluded 27 studies in this review. See Characteristics of
excluded studies table.
Thriteen studies were in paediatric or combined paediatric-adult
populations, with no separate data available for adults. Six studies
implemented patient-controlled analgesia (PCA). In two studies,
pain was not measured as an outcome but VOC was measured as
the outcome. Six studies were either not double-blind or were an
open-label trial.
Studies awaiting classification
See Studies awaiting classification table.
De Castro 2013 and Perlin 1988 are conference abstracts which
currently meet eligibility criteria but require outcome data. We
contacted the study authors for further information so these remain
in studies awaiting classification. In Teuscher 1989, it was unclear
whether pain was reported as a primary or secondary outcome. We
contacted the study author for further information but this has not
been received.
Ongoing studies
We identified three ongoing studies (IRCT2016072511956N6;
NCT03431285; NCT03978156). See Characteristics of ongoing
studies table.
Risk of bias in included studies
A summary of the risk of bias assessment is available in Figure 2.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 
Full details of risk of bias assessments are available in the
Characteristics of included studies table.
Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
18
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Allocation
Random sequence generation
Four studies adequately described the methods used to randomize
participants (computer-generated randomization) and were at low
risk of selection bias for random sequence generation (Benjamin
1986; De Franceschi 2016; Perlin 1994; Wright 1992). Five studies
did not adequately describe the methods used to randomize
participants and were at unclear risk of selection bias for random
sequence generation (Arambasik 2013; Bartolucci 2009; Gonzalez
1988; Qari 2007; Rehmani 2013). No studies displayed a high risk of
selection bias for random sequence generation.
Allocation concealment
Three studies adequately described the methods used to conceal
allocation of treatment to each group and were at low risk of
selection bias for allocation concealment (Benjamin 1986; Perlin
1994; Wright 1992). Six studies did not adequately describe the
methods used to conceal allocation of treatment to each group and
were at unclear risk of selection bias for allocation concealment
(Arambasik 2013; Bartolucci 2009; De Franceschi 2016; Gonzalez
1988; Qari 2007; Rehmani 2013). No studies displayed a high risk of
selection bias for allocation concealment.
Blinding
Performance bias
Four studies adequately described the methods to blind both
participants and study personnel from knowledge of the treatment
groups and were at low risk of performance bias (Benjamin 1986;
Gonzalez 1988; Perlin 1994; Wright 1992). Five studies did not
adequately describe the methods to blind both participants and
study personnel from knowledge of the treatment groups and were
at unclear risk of performance bias (Arambasik 2013; Bartolucci
2009; De Franceschi 2016; Qari 2007; Rehmani 2013). No studies
displayed a high risk of performance bias.
Detection bias
Three studies adequately described the methods used to conceal
and blind the outcome assessors from knowledge of the treatment
groups and were at low risk of detection bias (De Franceschi 2016;
Gonzalez 1988; Perlin 1994). Six studies did not adequately describe
the methods used to conceal and blind the outcome assessors from
knowledge of the treatment groups and were at unclear risk of
detection bias (Arambasik 2013; Bartolucci 2009; Benjamin 1986;
Qari 2007; Rehmani 2013; Wright 1992). No studies displayed a high
risk of detection bias.
Incomplete outcome data
Two studies adequately accounted for all participants from
the recruitment stage, through randomization until follow-up,
including counting all withdrawals and were at low risk of
attrition bias (De Franceschi 2016; Wright 1992). Six studies did
not adequately account for all participants from the recruitment
stage, through randomization until follow-up, including counting
all withdrawals and were at unclear risk of attrition bias (Arambasik
2013; Benjamin 1986; Gonzalez 1988; Perlin 1994; Qari 2007;
Rehmani 2013). One study reported 20% attrition, the outcome
reporting ignored these randomized participants and analyses did
not appear to be by intention to treat (Bartolucci 2009). This was at
high risk of attrition bias.
Selective reporting
Six studies adequately reported in their results all the outcomes
that were planned in the methods sections and were at low risk of
reporting bias (Bartolucci 2009; Benjamin 1986; De Franceschi 2016;
Gonzalez 1988; Perlin 1994; Wright 1992). One study displayed an
unclear risk of reporting bias and was at unclear risk of reporting
bias (Arambasik 2013). Two studies, planned to measure outcomes
in their methods, but did not mention them when reporting results
and were at high risk of reporting bias (Qari 2007; Rehmani 2013).
Qari 2007 did not report on adverse events or opioid consumption,
as planned. Rehmani 2013 did not report on the VRS, as planned.
Other potential sources of bias
Size
Two studies investigated between 50 and 200 participants per
treatment arm and were at unclear risk of bias in relation to size
(Qari 2007; Rehmani 2013).
Seven studies investigated fewer than 50 participants per
treatment arm and were at high risk of bias in relation to size
(Arambasik 2013; Bartolucci 2009; Benjamin 1986; De Franceschi
2016; Gonzalez 1988; Perlin 1994; Wright 1992). No studies
investigated more than 200 participants per treatment arm.
Other
Gonzalez 1988 displayed a high risk of bias in relation to a unit of
analysis issue, 12 events per treatment arm. However, the unit of
randomization was the painful crisis (45 randomized crises events
among 18 participants), random-e#ects analysis took this unit of
analysis issue appropriately into account. This was judged at high
risk of 'other' bias.
Bartolucci 2009 displayed some unclear risk of bias in relation to
a unit of analysis error. The unit of randomization was the painful
crisis (66 randomized crises among 54 participants), but the unit
of analysis ignored the clustered nature of the data which were
analysed as if all randomized events were independent. This was
judged at unclear risk of 'other' bias.
Arambasik 2013 displayed some unclear risk of bias as we could not
conclude there was low risk of bias due to only the abstract being
available. This was judged at unclear risk of 'other' bias.
For the remaining six studies, we found no other potential sources
of bias and they were at low risk of 'other' bias.
E=ects of interventions
See: Summary of findings for the main comparison Non-
steroidal anti-inflammatory drugs (NSAID) compared with placebo
for painful sickle cell vaso-occlusive crises; Summary of findings
2 Opioids compared with placebo for painful sickle cell vaso-
occlusive crises; Summary of findings 3 Opioids compared with
active comparator for painful sickle cell vaso-occlusive crises
For results and adverse events of individual studies, see Appendix
2 (primary outcome data: pain outcomes); Appendix 3 (secondary
outcome data); and Appendix 4 (adverse events and withdrawals).
Table 1 displays the types of pharmacological intervention
comparisons by study.
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Table 1: types of drug comparisons
 
Study Interventions Comparison pair
Arambasik 2013 Ketamine + hydromorphone vs placebo + hydromorphone Opioid vs placebo
Bartolucci 2009 Ketoprofen vs placebo NSAID vs placebo
Benjamin 1986 Cetiedil vs placebo Vasodilator (anti-sickling) vs placebo
De Franceschi 2016 Ketorolac + tramadol + metoclopramide + fentanyl vs ketoro-
lac + tramadol + metoclopramide
Combination vs combination
Gonzalez 1988 Butorphanol vs morphine Opioid vs opioid
Perlin 1994 Ketorolac vs placebo NSAID vs placebo
Qari 2007 Tinzaparin vs placebo Anticoagulant vs placebo
Rehmani 2013 Morphine vs paracetamol Opioid vs paracetamol
Wright 1992 Ketorolac vs placebo NSAID vs placebo
 
Comparison 1: non-steroidal anti-inflammatory drugs versus
placebo
Three studies compared an NSAID with placebo (Bartolucci 2009;
Perlin 1994; Wright 1992). See Summary of findings for the main
comparison.
Primary outcomes
Participant-reported pain relief of 50% or greater
None of the studies reported participants-reported pain relief of
50% or greater.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Participant-reported pain relief of 30% or greater
None of the studies reported participant-reported pain relief of 30%
or greater.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Patient Global Impression of Change very much improved
One study reported PGIC very much improved (Perlin 1994). As
there was only one study reporting this comparison, we did not
undertake a meta-analysis but provided a summary of e#ects from
the individual study (RR: risk ratio); Analysis 1.1; Figure 3.
 
Figure 3.   Forest plot of comparison: 1 Non-steroidal anti-inflammatory drugs (NSAIDs) versus placebo, outcome:
1.1 Patient Global Impression of Change very much improved.
 
Perlin 1994 reported very much improved for 3/10 participants
in the ketorolac group, and for 0/11 participants in the placebo
group (RR 7.64, 95% CI 0.44 to 131.75; P = 0.16; Analysis 1.1; Figure
3). As there were too few data for this outcome (limited number
of participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Patient Global Impression of Change much or very much improved
One study reported PGIC much or very much improved (Perlin 1994).
As there was only one study reporting this comparison, we did not
undertake a meta-analysis but provided a summary of e#ects from
the individual study (RR: risk ratio); Analysis 1.2; Figure 4.
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Figure 4.   Forest plot of comparison: 1 Non-steroidal anti-inflammatory drugs (NSAIDs) versus placebo, outcome:
1.2 Patient Global Impression of Change much or very much improved.
 
Perlin 1994 reported the combination of much or very much
improved for 6/10 participants in the ketorolac group, and 4/11
participants in the placebo group (RR 1.65, 95% CI 0.65 to 4.19; P =
0.29; Analysis 1.2; Figure 4).
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Secondary outcomes
Opioid consumption
Three studies reported opioid consumption (Bartolucci 2009; Perlin
1994; Wright 1992).
Bartolucci 2009 reported the use of additional rescue morphine.
The overall median (interquartile range (IQR)) consumption of
morphine was 110 mg (IQR 46 to 195) in the ketoprofen group and
88 mg (IQR 52.5 to 262.5) in the placebo group (33 participants per
group).
Perlin 1994 reported the use of additional rescue meperidine. The
mean daily dose of meperidine was 523.6 mg (standard deviation
(SD) 222.1) in the ketorolac group (10 participants) and 662.4 mg
(SD 68.6) in the placebo group (11 participants). The overall mean
consumption of meperidine was 1866.7 mg (SD 1112.4) in the
ketorolac group and 2804.5 mg (SD 795.1) in the placebo group.
Wright 1992 reported the use of additional rescue meperidine. The
overall mean consumption of meperidine was 231 mg (SD 92) in
the ketorolac group and 250 mg (SD 85) in the placebo group (12
participants per group).
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Time to pain resolution
One study reported time to pain resolution (Bartolucci 2009).
Bartolucci 2009 reported median time to participants' resolution
of pain as 51 hours (IQR 35.5 to 87) in the ketoprofen group and
50 hours (IQR 36 to 103) in the placebo group (33 participants per
group). As there were too few data for this outcome (limited number
of participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Length of hospitalization
One study reported length of hospitalization (Perlin 1994).
Perlin 1994 reported mean length of hospitalization as 3.3 days in
the ketorolac group (10 participants) and 7.2 days in the placebo
group (11 participants) (P < 0.05). As there were too few data for this
outcome (limited number of participants per treatment arm), we
had no confidence in the results and we downgraded the quality of
evidence by three levels to very low quality.
Participants experiencing any adverse or serious adverse event
Two studies reported adverse events (Bartolucci 2009; Wright
1992).
Bartolucci 2009 reported any mild adverse events in 16/33
participants in the ketoprofen group and 19/33 participants in the
placebo group.
Wright 1992 reported adverse events in 0/12 participants in the
ketorolac group and 0/12 participants in the placebo group.
Three studies reported serious adverse events (Bartolucci 2009;
Perlin 1994; Wright 1992).
Bartolucci 2009 reported serious adverse events in 1/33
participants in the ketoprofen group, and 2/33 participants in the
placebo group.
Perlin 1994 reported serious adverse events in 0/10 participants in
the ketorolac group and 0/11 participants in the placebo group.
Wright 1992 reported serious adverse events in 0/12 participants in
the ketorolac group and 0/ 12 participants in the placebo group.
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Any pain-related outcome indicating some improvement
Three studies reported additional pain related outcome data
(Bartolucci 2009; Perlin 1994; Wright 1992).
Bartolucci 2009 reported the mean daily scores on a categorical
pain scale (0 to 3) as median 0.4 (IQR 0.2 to 0.7) in the ketoprofen
group and 0.4 (IQR 0.2 to 0.7) in the placebo group. The authors also
reported mean daily scores on a VAS (0 mm to 100 mm, where 0 = no
pain) as median 12.6 (IQR 4.8 to 23.2) in the ketoprofen group and
9.6 (IQR 5.8 to 33.2) in the placebo group.
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Perlin 1994 reported the pain scores at baseline on a VAS (0 mm to
100 mm), as mean 77.7 (95% CI 69.1, 86.2) in the ketorolac group
and 79.1 (95% CI 72.1 to 86.0) in the placebo group. Pain scores
at 24 hours on a VAS (0 mm to 100 mm) were mean 58.6 (95% CI
48.6 to 68.5) in the ketorolac group and 72.6 (95% CI 62.4 to 82.8)
in the placebo group (P < 0.05). Mean pain scores at baseline on a
visual categorical scale (0 to 3) were 2.5 in the ketorolac group and
2.6 in the placebo group. Mean pain scores at 24 hours on a visual
categorical scale (0 to 3) were 2.0 in the ketorolac group and 2.4 in
the placebo group. Mean pain scores at 24 hours on a VRS (0 to 4)
were 1.8 in the ketorolac group and 1.9 in the placebo group.
Wright 1992 reported mean pain scores at baseline on a VAS (0 mm
to 100 mm) were 70.3 in the ketorolac group and 79.3 in the placebo
group (P = 0.26). Mean pain scores at four hours on a VAS (0 mm to
100 mm) were 44 (SD 34) in the ketorolac group and 37 (SD 31) in
the placebo group (P = 0.49).
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Withdrawals: due to lack of e=icacy, adverse events and for any cause
Two studies reported all-cause withdrawals (Perlin 1994; Wright
1992).
Perlin 1994 reported total all-cause withdrawals in 1/10
participants in the ketorolac group and 0/11 participants in the
placebo group.
Wright 1992 reported total all-cause withdrawals in 0/12
participants in the ketorolac group and 0/12 participants in the
placebo group.
Three studies reported withdrawals due to adverse events
(Bartolucci 2009; Perlin 1994; Wright 1992).
Bartolucci 2009 reported withdrawals due to adverse events in 1/33
participants in the ketoprofen group and 1/33 participants in the
placebo group.
Perlin 1994 reported withdrawals due to adverse events in 0/10
participants in the ketorolac group and 0/11 participants in the
placebo group.
Wright 1992 reported withdrawals due to adverse events in 0/12
participants in the ketorolac group and 0/12 participants in the
placebo group.
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Reports of tolerance or habituation to opioids
None of the studies reported tolerance or habituation to opioids.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Comparison 2: opioids versus placebo
One study compared ketamine plus hydromorphone with placebo
plus hydromorphone (Arambasik 2013). See Summary of findings 2.
Primary outcomes
Participant-reported pain relief of 50% or greater
The study did not report participant-reported pain relief of 50% or
greater.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Participant-reported pain relief of 30% or greater
The study did not report participant-reported pain relief of 30% or
greater.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Patient Global Impression of Change very much improved
The study did not report PGIC very much improved.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Patient Global Impression of Change much or very much improved
The study did not report PGIC much or very much improved.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Secondary outcomes
Opioid consumption
The study did not report opioid consumption.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Time to pain resolution
The study did not report time to pain resolution.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Length of hospitalization
The study did not report length of hospitalization.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Participants experiencing any adverse or serious adverse event
The study did not report any adverse event or serious adverse
event.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Any pain-related outcome indicating some improvement
Arambasik 2013 reported mean pain scores on a VAS (1 to 10,
where 1 implies none or minimal pain), on arrival, of 8.7 (95% CI
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8.07 to 9.29) in the ketamine plus hydromorphone group and 8.5
(95% CI 7.90 to 9.05) in the placebo plus hydromorphone group.
At administration of the study drugs, mean pain scores were 6.0
(95% CI 4.71 to 7.29; a 31% decrease from arrival) in the ketamine
plus hydromorphone group and 7.0 (95% CI 6.20 to 7.85; a 17.6%
decrease from arrival) in the placebo plus hydromorphone group.
Once doses were administered, the mean pain scores were 5.2 (95%
CI 4.01 to 6.46; a 40.2% decrease from arrival) in the ketamine
plus hydromorphone group and 5.6 (95% CI 4.27 to 6.93; a 34.1%
decrease from arrival) in the placebo plus hydromorphone group.
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Withdrawals: due to lack of e=icacy, adverse events and for any cause
The study did not report withdrawals.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Reports of tolerance or habituation to opioids
The study did not report tolerance or habituation to opioids.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Comparison 3: opioids versus active comparator
Two studies compared an opioid with an active comparator:
Gonzalez 1988: morphine versus butorphanol; Rehmani 2013:
morphine versus paracetamol. See Summary of findings 3.
Primary outcomes
Participant-reported pain relief of 50% or greater
Neither study reported participant-reported pain relief of 50% or
greater.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Participant-reported pain relief of 30% or greater
Neither study reported participant-reported pain relief of 30% or
greater.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Patient Global Impression of Change very much improved
One study reported PGIC very much improved (Gonzalez 1988).
Gonzalez 1988 reported an equivalent scale of very much improved
as 'excellent' for 19.1% of events in the butorphanol group and
33.3% of events in the morphine group.
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Patient Global Impression of Change much or very much improved
One study reported PGIC much or very much improved (Gonzalez
1988).
Gonzalez 1988 reported equivalent scales of 'good' and 'excellent'.
The study reported 'good' improvement from 47.6% in the
butorphanol group and 38.1% in the morphine group. The study
reported 'excellent' improvement from 19.1% in the butorphanol
group and 33.3% in the morphine group. The study did not report a
combination of 'good and excellent' (equivalent scale of much and
very much improved) and the available percentages did not seem to
match the raw data, so it was not possible to calculate a combined
percentage for this outcome.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Secondary outcomes
Opioid consumption
One study reported opioid consumption.
Rehmani 2013 reported the use of additional rescue morphine 0.1
mg/kg at 30 minutes for 27/54 participants in the morphine group,
and 24/52 participants in the paracetamol group.
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Time to pain resolution
Neither study reported time to pain resolution.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Length of hospitalization
Neither study reported length of hospitalization.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Participants experiencing any adverse or serious adverse event
Both studies reported adverse events and serious adverse events.
Gonzalez 1988 reported nausea and vomiting in 4/12 participants
in the butorphanol group and 4/12 participants in the morphine
group.
Rehmani 2013 reported mild adverse events in 5/54 participants
in the morphine group and 3/52 participants in the paracetamol
group.
Gonzalez 1988 reported serious adverse events in 0/12 participants
in the morphine group and 0/12 participants in the butorphanol
group.
Rehmani 2013 reported serious adverse events 0/54 participants
in the morphine group and 0/52 participants in the paracetamol
group.
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As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Any pain-related outcome indicating some improvement
Both studies reported mean pain scores, at di#erent time points.
Gonzalez 1988 reported adjusted mean overall pain scores, on a VAS
(0 mm to 100 mm, where 0 = no pain) of 46.08 in the morphine group
and 44.42 in the butorphanol group. Adjusted mean overall pain
scores, on a Pain Relief Scale (0 mm to 100 mm, where 0 = no pain)
were 55.50 in the morphine group and 43.79 in the butorphanol
group.
Rehmani 2013 reported mean pain scores, on a VAS (0 mm to 100
mm, where 0 = no pain), at 30 minutes, of 44 (95% CI 33 to 56) in the
morphine group and 41 (95% CI 32 to 49) in the butorphanol group.
This was not statistically significant (P = 0.72).
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Withdrawals: due to lack of e=icacy, adverse events and for any cause
Neither study reported withdrawals.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Reports of tolerance or habituation to opioids
Neither study reported tolerance or habituation to opioids.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Comparison 4: 'other' active comparators versus placebo
Two studies investigated an active comparator compared with a
placebo: Benjamin 1986: vasodilator (cetiedil) versus placebo; Qari
2007: anticoagulant (tinzaparin) versus placebo.
Primary outcomes
Participant-reported pain relief of 50% or greater
Neither study reported participant-reported pain relief of 50% or
greater.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Participant-reported pain relief of 30% or greater
Neither study reported participant-reported pain relief of 30% or
greater.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Patient Global Impression of Change very much improved
Neither study reported PGIC very much improved.
See Appendix 2 for further details reported by Benjamin 1986.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Patient Global Impression of Change much or very much improved
One study reported PGIC much or very much improved (Benjamin
1986).
Benjamin 1986 reported 'good + excellent' (an equivalent scale
to much or very much improvement) for 9/16 participants in the
cetiedil 0.2 mg/kg group, 10/18 participants in the cetiedil 0.3 mg/
kg group, 11/13 participants in the cetiedil 0.4 mg/kg group and
4/16 participants in the placebo group.
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Secondary outcomes
Opioid consumption
Neither study reported opioid consumption.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Time to pain resolution
One study reported time to pain resolution.
Qari 2007 reported mean time to participants' resolution of pain
as 61.68 hours in the tinzaparin group (127 participants) and 104.4
hours in the placebo group (126 participants).
We considered the available data for this outcome to be low-quality
evidence, downgraded once for sparse data, and once for high
probability of reporting bias.
Length of hospitalization
One study reported length of hospitalization.
Qari 2007 reported mean length of hospitalization as 7.08 days
hours in the tinzaparin group (127 participants) and 12.06 in the
placebo group (126 participants).
We considered the available data for this outcome to be low-quality
evidence, downgraded once for sparse data, and once for high
probability of reporting bias.
Participants experiencing any adverse or serious adverse event
One study reported adverse events and serious adverse events.
Benjamin 1986 reported headache, nausea, vomiting and dry
mouth in 2/17 participants in the cetiedil 0.2 mg/kg group, 9/18
participants in the cetiedil 0.3 mg/kg group, 8/14 participants in the
cetiedil 0.4 mg/kg group and 8/18 participants in the placebo group.
Benjamin 1986 reported no serious adverse events in the cetiedil
0.2 mg/kg group (0/16 participants), cetiedil 0.3 mg/kg group (0/18
participants), cetiedil 0.4 mg/kg group (0/13 participants) and the
placebo group (0/16 participants).
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
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results and we downgraded the quality of evidence by three levels
to very low quality.
Any pain-related outcome indicating some improvement
Neither study reported any pain-related outcome indicating some
improvement.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Withdrawals: due to lack of e=icacy, adverse events and for any cause
Neither study reported withdrawals.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Reports of tolerance or habituation to opioids
Neither study reported tolerance or habituation to opioids.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Comparison 5: combination pharmacotherapy versus
combination pharmacotherapy
One study compared ketorolac plus tramadol plus metoclopramide
plus fentanyl (KTMF) with ketorolac plus tramadol plus
metoclopramide (KTM) (De Franceschi 2016).
Primary outcomes
Participant-reported pain relief of 50% or greater
De Franceschi 2016 reported participant-reported pain relief of 50%
or greater at six hours for 12/20 participants in the KTMF group and
0/20 participants in the KTM group.
De Franceschi 2016 reported participant-reported pain relief of 50%
or greater at 12 hours for 18/20 participants in the KTMF group and
4/20 participants in the KTM group.
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Participant-reported pain relief of 30% or greater
De Franceschi 2016 reported participant-reported pain relief of 30%
or greater at six hours for 20/20 participants in the KTMF group and
1/20 participants in the KTM group.
De Franceschi 2016 reported participant-reported pain relief of 30%
or greater at 12 hours for 20/20 participants in the KTMF group and
4/20 participants in the KTM group.
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Patient Global Impression of Change very much improved
The study did not report PGIC very much improved.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Patient Global Impression of Change much or very much improved
The study did not report PGIC much or very much improved.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Secondary outcomes
Opioid consumption
The study did not report opioid consumption.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Time to pain resolution
The study did not report time to pain resolution.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Length of hospitalization
The study did not report length of hospitalization.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Participants experiencing any adverse or serious adverse event
De Franceschi 2016 reported adverse events as 0/20 in the KTMF
group and 0/20 in the KTM group.
De Franceschi 2016 reported serious adverse events as 0/20 in the
KTMF group and 0/20 in the KTM group.
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Any pain-related outcome indicating some improvement
The study did not report any pain-related outcome indicating some
improvement.
As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
Withdrawals: due to lack of e=icacy, adverse events and for any cause
De Franceschi 2016 reported total all-cause withdrawals as 0/20 in
the KTMF group and 0/20 in the KTM group.
De Franceschi 2016 reported withdrawals due to adverse events as
0/20 in the KTMF group and 0/20 in the KTM group.
As there were too few data for this outcome (limited number of
participants per treatment arm), we had no confidence in the
results and we downgraded the quality of evidence by three levels
to very low quality.
Reports of tolerance or habituation to opioids
The study did not report tolerance or habituation to opioids.
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As there were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
D I S C U S S I O N
Summary of main results
We included nine studies in this review with data for 638 VOC events
and 594 participants aged 17 to 42 years with sickle cell disease
presenting to a hospital emergency department in a painful VOC.
Three studies compared NSAID with placebo for which we were
unable to undertake a meta-analysis. One study compared an
opioid with a placebo, two studies compared an opioid with an
active comparator, two studies compared an anticoagulant with a
placebo, and one study compared a combination of three drugs
with a combination of four drugs.
Risk of bias across the nine studies varied. For randomization
and allocation concealment, studies were mostly at an unclear
risk of bias, with only three studies adequately describing
their randomization methods (low risk). For blinding, studies
primarily displayed an unclear risk of bias, with only two studies
clearly describing blinding methods of participants, personnel
and outcome assessors methods (low risk). For attrition, studies
primarily displayed an unclear risk of bias, with only two studies
clearly accounting for all participants (low risk), and one study not
at all (high risk). For reporting, studies primarily displayed a low
risk of bias, with two studies poorly reporting planned outcomes
(high risk) and one study unclearly reporting planned outcomes
(low risk). For size, studies primarily displayed a high risk of bias
with fewer than 50 participants per treatment arm, and two studies
with 50 to 199 participants per treatment arm (unclear risk). For
other risks of bias, studies primarily displayed a low risk of bias,
with two studies showing uncertainties in their procedures (unclear
risk) and one study displaying a high risk of bias.
Pain outcomes: only one study (under comparison 5: Combination
pharmacotherapy versus combination pharmacotherapy) reported
participant-reported pain relief of 50% or greater and 30% or
greater; so due to a lack of available data we were unable to
undertake a meta-analysis (De Franceschi 2016). Three studies
reported Patient Global Impression of Change very much improved,
and much or very much improved, however, due to lack of data, we
were unable to undertake a meta-analysis.
1: Non-steroidal anti-inflammatory drugs (NSAID) compared
with placebo
For PGIC very much improved, we found no di#erences between
ketorolac and placebo (RR 7.64, 95% CI 0.44 to 131.75; P = 0.16;
Analysis 1.1; Figure 3), or for PGIC much or very much improved
(RR 1.65, 95% CI 0.65 to 4.19; P = 0.29; Analysis 1.2; Figure 4) (one
study, 21 participants, very low-quality evidence).
For opioid consumption (rescue morphine), we found no
di#erences between ketoprofen (overall median consumption 110
mg, IQR 46 to 195) and placebo (88 mg, IQR 52.5 to 262.5) (one study,
very low-quality evidence). The same for rescue meperidine,
no di#erences were reported between ketorolac (1866.7 mg,
SD 1112.4) compared with placebo (2804.5 mg, SD 795.1), and
ketorolac (231 mg, SD 92) compared with placebo (250 mg, SD 85)
(two non-comparable RCTs, very low-quality evidence).
For median time to participants' resolution of pain, we found
no di#erences between ketoprofen (51 hours, IQR 35.5 to 87) and
placebo (50 hours, IQR 36 to 103) (33 participants per group, one
study, very low-quality evidence).
For mean length of hospitalization, we found a di#erence
between ketorolac (3.3 days) and placebo (7.2 days) (P < 0.05) (21
participants, one study, very low-quality evidence).
Mild adverse events were reported in the ketoprofen (16/33),
placebo (19/45), and ketorolac (0/12) study arms (two studies, very
low-quality evidence). Serious adverse events (not specified) were
reported in the ketoprofen (1/33), placebo (2/56), and ketorolac
(0/22) study arms (three studies, very low-quality evidence).
For any pain-related outcome indication some improvement, we
found a di#erence in mean change in pain scores between ketorolac
and placebo, from baseline to 24 hours, on a VAS 0 to 100 mm:
ketorolac baseline (77.7, 95% CI 69.1, 86.2) to 24 hours (58.6, 95%
CI 48.6 to 68.5), and placebo baseline (79.1, 95% CI 72.1 to 86.0)
to 24 hours (72.6, 95% CI 62.4 to 82.8) (P < 0.05) (one study, very
low-quality evidence). However, other scales used to measure pain
(VCS 0 to 3, VRS 0 to 4, VAS at 4 hours) reported no di#erences
between ketorolac and placebo, the same for ketoprofen compared
with placebo (three studies, very low-quality evidence).
Withdrawals due to adverse events were reported in ketoprofen
(1/33), ketorolac (0/22), and placebo (1/56) (three studies, very low-
quality evidence).
2: Opioids compared with placebo
For any pain-related outcome indication some improvement,
we found no di#erence in mean pain scores between ketamine/
hydromorphone and placebo/hydromorphone on a VAS (1 to 10
cm): ketamine/hydromorphone (5.2 cm; 95% CI 4.01 to 6.46; 40.2%
decrease from baseline), placebo/hydromorphone (5.6 cm; 95% CI
4.27 to 6.93; 34.1% decrease from baseline) (one study, very low-
quality evidence).
3: Opioids compared with active comparator
For PGIC very much improved, the outcome was reported as
'excellent' in 19.1% of butorphanol and 33% of morphine events
(one study, very low-quality evidence).
For opioid consumption (rescue morphine 0.1 mg/kg taken at
30 minutes), we found no di#erence between morphine (27/54)
and paracetamol participants (24/52) (one study, very low-quality
evidence).
Mild adverse events (nausea and vomiting) were reported in
butorphanol (4/12), morphine (9/66), and paracetamol (3/52). No
serious adverse events were reported in any treatment group
(0/132 participants) (two studies, very low-quality evidence).
For any pain-related outcome indication some improvement, we
found no di#erence between the adjusted mean pain scores using:
VAS (0 to 100 mm) morphine (46.08 mm) and butorphanol (44.42
mm); or PRS (0 to 100 mm) morphine (55.50 mm) and butorphanol
(43.79 mm) (one study, very low-quality evidence).
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4: Other active comparator compared with placebo
For PGIC much or very much improved, we found no di#erences
between cetiedil 0.2 mg/kg (9/16 participants), cetiedil 0.3 mg/kg
(10/18), cetiedil 0.4 mg/kg (11/13), and placebo (4/16) (one study,
very low-quality evidence).
For mean time to participants' resolution of pain, we found
no di#erences between tinzaparin (61.68 hours, 127 participants)
and placebo (104.4 hours, 126 participants) (one study, low quality
evidence).
For mean length of hospitalization, we found no di#erences
between tinzaparin (7.08 days, 127 participants) and placebo (12.06
days, 126 participants) (one study, low quality evidence).
Any adverse events (headache, nausea, vomiting and dry mouth)
were reported in cetiedil 0.2 mg/kg (2/17), cetiedil 0.3 mg/kg (9/18),
cetiedil 0.4 mg/kg (8/14), and placebo (8/18) (one study, very low-
quality evidence). No serious adverse events were reported in any
groups (one study, very low-quality evidence).
5: Combination pharmacotherapy compared with combination
pharmacotherapy
For participant-reported pain relief of 50% or greater, we
found no di#erences between ketorolac plus tramadol plus
metoclopramide plus fentanyl (KTMF) (12/20) and ketorolac plus
tramadol plus metoclopramide (KTM) (0/20) at six hours, and no
di#erences between KTMF (18/20) and KTM (4/20) at 12 hours (one
study, very low-quality evidence).
For participant-reported pain relief of 30% or greater, we found
this was reported in 20/20 participants for KTMF and in 1/20
participants for KTM (at six hours), and in 20/20 participants for
KTMF and in 4/20 participants for KTM (at 12 hours) (one study, very
low-quality evidence).
Adverse events, serious adverse events, and total all-cause
withdrawals were reported in KTMF (0/20) and KTM (0/20) (one
study, very low-quality evidence).
Overall completeness and applicability of evidence
This review identified only nine studies, with insu#icient data for all
pharmacological interventions for analysis.
As we were unable to undertake a meta-analysis for each drug
comparison (only a summary of e#ects from individual studies),
we were unable to comment about e#icacy or harm from the
use of pharmacological interventions to treat painful sickle cell
VOC in adults. Similarly we could not comment on our remaining
secondary outcomes: opioid consumption, time to pain resolution,
length of hospitalization and opioid tolerance.
Quality of the evidence
Of the nine included studies, only four adequately described
randomization methods, and only three adequately described
single- or double-blinding methods. One study displayed a high risk
of attrition bias and two studies displayed a high risk of selective
reporting bias. Seven studies displayed a high risk of size bias
with study samples fewer than 50 participants per treatment arm,
and the remaining two were unclear risk of size bias. Only seven
studies provided su#icient information about adverse events, and
four studies about withdrawals.
The studies recruited participants with adequate baseline pain in a
VOC, but not all reported clinically useful outcome measures.
The studies themselves were of moderate quality; however, the
number of studies and sample sizes for some comparisons were
limited, given what is known about study size and estimates of
e#ect for outcomes derived from studies with few participants and
events (Dechartres 2013; Dechartres 2014; McQuay 1998; Nüesch
2010; Thorlund 2011).
We downgraded the quality of the evidence for our primary
outcomes to very low quality for the reason:
• Due to too few data for these outcomes (limited number of
participants per treatment arm) as we had no confidence in the
results.
In some comparisons, and for some outcomes, there were no data
available, so we reported this as:
• There were no data for this outcome, the quality of evidence is
unknown, and there is no evidence to support or refute.
We applied the same approach to our secondary outcomes.
Potential biases in the review process
We used a comprehensive and highly sensitive search strategy in
the major databases, in addition to two large clinical trial registries.
We consider it unlikely that we missed relevant studies.
We followed standard Cochrane methods and there were no
contestable decisions relating to the inclusion or exclusion of
studies, data analyses, or assessing risk of bias. There were no
contestable decisions relating to the synthesis of studies.
Agreements and disagreements with other studies or
reviews
This is the first Cochrane Review, and the first systematic review
that we are aware of that encompasses the search of all drugs
implemented during a VOC.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
For people with sickle cell disease
The amount and quality of evidence around the use of any
pharmacological treatment for painful sickle cell vaso-occlusive
crises (VOC) is very low. This means treatment is based on clinical
experience and advice from respected authorities. We could make
no judgement about which pharmacological treatment is more
e#ective than any other to reduce the painful crisis. We could make
no judgement about adverse events or withdrawals.
Sickle cell pain should be treated by specialists in this area.
For clinicians
The amount and quality of evidence around the use of any
pharmacological treatment for painful sickle cell VOC is very low.
This means treatment is based on clinical experience and advice
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from respected authorities. We could make no judgement about
which pharmacological treatment is more e#ective than any other
to reduce the painful crisis. We could make no judgement about
adverse events or withdrawals.
Clinicians who do not have expertise in this field should defer to
clinicians with specialist knowledge.
For policy makers and funders of the intervention
The amount and quality of evidence around the use of any
pharmacological treatment for painful sickle cell VOC is very low.
This means treatment is based on clinical experience and advice
from respected authorities. We could make no judgement about
which pharmacological treatment is more e#ective than any other
to reduce the painful crisis. We could make no judgement about
adverse events or withdrawals.
Specialist services treating people with sickle cell disease will need
to be supported (by clinical expertise and multi-factorial service
models) to provide adequate treatment.
Implications for research
The results of this review are disappointing with fewer than 600
participants included in relevant randomized controlled trials.
While it would be easy to suggest more trials are needed, and they
probably are, it may be that a di#erent approach is necessary.
One possible route is the establishment of suitable registries for
this group of people which records interventions and outcomes.
To achieve any progress, thought needs to be given to relevant
outcomes for this patient group.
With the advent of precision medicine, the use of analgesics
in general and opioids in particular should be based on recent
advances in the pharmacodynamics and pharmacokinetics of
opioids. Pharmacodynamically, opioids are ligands that bind and
activate specific receptors that modulate the transmission of
painful stimuli in the central nervous system. Accordingly, the
analgesic potential of a specific opioid depends on the number
of receptors and the ability of the opioid to bind to these
receptors. Since these factors vary among people, so does the
analgesic potential. In addition, pharmacokinetically, opioids are
metabolized by specific enzymes into metabolites that could be
analgesically active or inactive depending on the opioid being used.
These enzymes could be duplicated, triplicated, mutated or deleted
in di#erent people thus causing significant variation in pain relief
among patients. Hopefully, these pharmacological markers could
be determined for each person in the future which allows the choice
of the best opioid compatible with the person in question.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Allocation: randomized
Controlled: placebo and active comparator
Blinding: double-blind
Arm: 2-arm, parallel treatment group, pilot study
Centre: single centre
Study dates and duration: 16-month period trial (June 2011 to October 2012)
Participants Inclusion criteria: not reported
Exclusion criteria: not reported
Baseline characteristics
N: 37 participants; 37 VOC episodes
Age (mean): 29.9 years
Gender: F 13, M 24
Number randomized: 17 intervention, 20 control
Number completed: number of participants at each follow-up time not explicitly stated
Setting of recruitment and treatment: not reported
Country and sites: Akron General Medical Centre, Akron, OH, USA
Interventions Duration of treatment: individual time to resolution of crisis
Follow-up period: not reported
Treatment group (17 participants; 17 VOC episodes):
• IV hydromorphone 2 mg
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• 15 minutes later: IV hydromorphone 2 mg + IV ketamine 6.2 mg/kg
Control group (20 participants; 20 VOC episodes):
• IV hydromorphone 2 mg
• 15 minutes later: IV hydromorphone 2 mg + IV saline placebo 6.2 mg/kg
Cointerventions/additional analgesia: not reported
Outcomes Primary outcomes
• Pain score (VAS 0–10)
Secondary outcomes
• Not reported
Notes Abstract only, sufficient data on pain scores
Sources of funding: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "this pilot study was randomised, prospective, double-blinded trial."
Comment: unclear details of randomization.
Allocation concealment
(selection bias)
Unclear risk Quote: "this pilot study was randomised, prospective, double-blinded trial."
Comment: unclear details of concealment.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: "this pilot study was... double-blind..."
Comment: insufficient information, unclear method of blinding.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: insufficient information from abstract.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: insufficient information from abstract.
Selective reporting (re-
porting bias)
Unclear risk Comment: primary outcome was reported in methods and results. However,
unclear what other outcomes were from this abstract alone.
Size High risk Comment: total 37 participants, fewer than 50 participants per treatment
arm.
Other bias Unclear risk Comment: unclear due to only abstract available.
Arambasik 2013  (Continued)
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Blinding: double-blind
Arm: 2-arm, parallel treatment groups
Centre: single centre
Study duration: 39-month period trial (August 2000 to March 2003)
Participants Inclusion criteria: homozygous SCD participants' who had a severe VOC requiring hospitalization in
the internal medicine department.
Exclusion criteria: VOC lasting > 72 hr or < 24 hr; parenteral hydration > 24 hr; blood transfusion dur-
ing the previous month; any NSAID intake during the previous 7 days; pregnancy; history of drug abuse;
hypertension; leukocyte count > 30 × 109/L or < 4 × 109/L; presence at inclusion of an acute chest syn-
drome, defined as the association of 2 criteria among chest pain, radiological infiltrate and auscultato-
ry abnormality; severe anaemia requiring a blood transfusion at inclusion; psychiatric disorder or pro-
gressive visceral disease; and ketoprofen allergy or NSAID contraindication; peptic ulcer or treated with
1 of the following drugs the week before enrolment: aspirin, valproic acid, macrolides, anti-H2, imida-
zole, rifampicin, phenobarbital, carbamazepine, phenytoin, heparin, vitamin K antagonist, ticlopidine,
lithium, methotrexate, interferon-α, diuretics or antihypertensive agents
Baseline characteristics
N: 54 participants; 66 VOC episodes
Gender: F 20, M 34
Age (mean): ≥ 15 years overall: 27 (SD 7) years intervention; 26 (SD 7) years control
Number randomized: 33 intervention; 33 control (VOC episodes)
Number completed: 26 intervention; 26 control (VOC episodes)
Setting and location: Adult Sickle Cell Referral Centre, Paris University Hospital, France
Interventions Treatment group (33 VOC episodes):
Days 1 and 2:
• IV infusion ketoprofen 300 mg, 2 days
• IV morphine 0.1 mg/kg every 5 minutes until pain relief achieved, followed by continuous morphine
infusion at initial dose of 2 mg/hr with repeated pulses until pain was well controlled
Days 3–5:
• oral ketoprofen 100 mg, every 8 hr
Control group (33 VOC episodes):
Days 1 and 2:
• continuous IV physiological saline (placebo), for 2 days
• IV morphine 0.1 mg/kg every 5 minutes until pain relief achieved, followed by continuous morphine
infusion at initial dose of 2 mg/hr with repeated pulses until pain was well controlled
Days 3–5:
• oral placebo, every 8 hr
Duration of treatment: 5 days
Follow-up period: up to 14 days postdischarge
Bartolucci 2009  (Continued)
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Cointerventions/additional analgesia: adjunctive standardized treatment: bed rest, < 3 L of 5% glu-
cose infusion, 1 L/day oral alkaline water, 20 mg/day folic acid, morphine dose not reported and IV
paracetamol 2 g every 8 hr for 48 hr, then 1 g every 8 hr)
Outcomes Primary outcomes
• Duration of VOC from inclusion (in hr); when at least ¾ were met: absence of fever for 8 hr, absence of
pain progression and no requirement of IV infusion of opioid analgesics for the last 8 hr
Secondary outcomes
• Morphine consumption during VOC
• Pain intensity by VAS; at baseline, every 4 hr
• Severity of pain assessed by CPS to grade pain at 7 body sites; at baseline and 12 hr
• Treatment failure, toxicity and adverse effects; reported on a standardized case report form
Notes Sources of funding: Inserm was the trial promoter. Publication costs of the article were defrayed in
part by page charge payments. The article was marked as advertising.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "patients were randomly assigned in a 1:1 ratio to either the interven-
tion or control group."
Comment: no details of randomization method.
Allocation concealment
(selection bias)
Unclear risk Comment: insufficient information of concealment.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: no information of details of the blinding process for either IV saline
or oral placebo.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: no statement of outcome assessment of blinding.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Quote: "7 VOCs each group were excluded from the analysis because of treat-
ment failures."
Comment: 20% attrition, and similar in each group. But outcome reporting ig-
nored these randomized participants, and analyses did not seem to be ITT.
Selective reporting (re-
porting bias)
Low risk Comment: all end points listed in the methods were reported in the results.
Size High risk Comment: total participants 54 (66 events), < 50 participants per treatment
arm.
Other bias Unclear risk Comment: unit of analysis error. Unit of randomization was the painful crisis
(66 randomized crises among 54 participants), but unit of analysis ignored the
clustered nature of the data; analysed as if all randomized events were inde-
pendent.
Bartolucci 2009  (Continued)
 
 
Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
37
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Methods Allocation: randomized
Controlled: placebo
Blinding: double-blind
Arm: 4 arms, parallel treatment groups
Centre: multicentre (5 centres)
Study dates and duration: not reported
Participants Inclusion criteria: known history of SCD (SS, SB/Thal), in a crisis lasting 4–24 hr. 1 crisis per participant
Exclusion criteria: pregnant, women of childbearing potential, incarceration, drug abuse history,
transfusion 90 days prior to trial, acute cerebrovascular accident, overt infection, renal failure with a
serum creatinine concentration > 2 mg percent (0.18 mmol/L), clinical or roentgenographic evidence
of pulmonary oedema, glaucoma, urinary retention, high sensitivity to anticholinergic or atropine-like
drugs
Baseline characteristics
N: 67 participants; 67 VOC episodes
Age: ≥ 19 years (67% aged 20–29) years
Gender: F 27, M 36
Setting and location: 5 state and university hospitals, and clinical centres, USA
Number randomized: 16 cetiedil 0.2 mg/kg group; 18 cetiedil 0.3 mg/kg group; 13 cetiedil 0.4 mg/kg
group; 16 control group
Number completed: 16 cetiedil 0.2 mg/kg group; 18 cetiedil 0.3 mg/kg group; 13 cetiedil 0.4 mg/kg
group; 16 control group
(63 included in efficacy analysis, 4 high haemoglobin A, all 67 included in safety analysis
Interventions Treatment group A (16 participants; 16 VOC episodes):
• IV cetiedil 0.2 mg/kg body weight in normal saline, every 8 hr, total of 12 doses
Treatment group B (18 participants; 18 VOC episodes):
• IV cetiedil 0.3 mg/kg body weight in normal saline, every 8 hr, total of 12 doses
Treatment group C (13 participants; 13 VOC episodes):
• IV cetiedil 0.4 mg/kg body weight in normal saline, every 8 hr, total of 12 doses
Control group (16 participants; 16 VOC episodes):
• 0.9 mg/mL normal IV saline, every 8 hr, total of 12 doses
Duration of treatment period: 4 days
Follow-up period: not reported
Cointerventions/additional analgesia: additional analgesics if required – limited to parenteral
meperidine hydrochloride 1.2 mg/kg, or oral paracetamol 300 mg with codeine phosphate 30 mg. Stan-
dard fluid replacement therapy
Outcomes Primary outcomes
• Pain intensity scale (numerical 0–3)
Benjamin 1986 
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Secondary outcomes
• Number of painful sites
• Duration of crisis (when 4 criteria met)
• Need for analgesic medication
• Investigator's overall evaluation of the participant' responses to study medication
Notes Sources of funding: supported by Johnson and Johnson Baby Products, McNeil Pharmaceutical, Inc
and by General Clinical Research Center Grants (RR 00102 and RR 00046) from the National Institutes of
Health and by the Veterans Administration Medical Service Research Fund.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "patients were randomly assigned at a central data centre." "The ran-
domization plan specified a coded ampule and a volume dosage for each pa-
tient."
Allocation concealment
(selection bias)
Low risk Quote: "Drug, active or placebo, was presented in identically appearing am-
pules. The investigators were aware of the volume of medication but were not
aware of the ampule's contents."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "The study was double-blind." "The investigators were aware of the
volume of medication by were not aware of the ampule's contents."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "The investigators were aware of the volume of medication but were
not aware of the ampule's contents."
Comment: not entirely clear whether this was extended to the pain evaluators
or research nurses being blind to the treatment groups when assessing pain.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: "Sixty-seven patients were entered in the trial. Sixty-three patients
were included in the analysis of efficacy. Four patients were found retrospec-
tively to have high hemoglobin."
Comment: reasonable retroactive application of exclusion criteria. Likely to
be fairly small attrition bias effect, but small numbers per treatment group, so
this randomization 'error' was unfortunate.
Selective reporting (re-
porting bias)
Low risk Comment: no protocol available, but all planned end points were reported in
results.
Size High risk Comment: total participants 67, < 50 participants per treatment arm.
Other bias Low risk Comment: no other possible sources of bias.
Benjamin 1986  (Continued)
 
 
Methods Allocation: randomized
Controlled: active comparators - combination pharmacotherapy
Blinding: double-blind
De Franceschi 2016 
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Arm: 2-arm crossover treatment
Centre: single centre
Study duration: January 2010 to July 2013
Participants Inclusion criteria: adults (aged 18–45 years) prior diagnosis of SCD, presenting to emergency depart-
ment with severe VOC (VAS 7+).
Exclusion criteria: opioid consumption in prior 2 weeks; history of opioid consumption (VOC or non-
SCD related); altered conscious state; pregnancy or lactating; hepatic or renal failures (or both); gastri-
tis; peptic ulcer; allergies to study drugs; cardiopulmonary disease, psychiatric conditions which may
compromise study responses.
Baseline characteristics
N: 20 participants; 40 VOC episodes
Gender: F 11, M 9
Age (median): 22 years (range 17–28 years)
Number randomized: 10 intervention; 10 control (VOC episodes)
Number completed: 10 intervention; 10 control (VOC episodes)
Setting and location: Department of Medicine, University of Verona, Italy
Interventions Treatment group VOC1 (10 participants; 20 VOC episodes):
• continuous IV infusion ketorolac 0.86 mg/kg/day + tramadol 7.2 mg/kg/day + metoclopramide 0.57
mg/kg/day, for maximum of 72 hr
Treatment group VOC2 (10 participants; 20 VOC episodes):
• continuous IV infusion ketorolac 0.86 mg/kg/day + tramadol 7.2 mg/kg/day + metoclopramide 0.57
mg/kg/day + fentanyl buccal single tablet 100 μg after 3 hr from beginning of multimodal analgesia,
for maximum of 72 hr
Outcomes Primary outcomes
• Time-weighted-sum pain intensity differences (SPID24) (VAS 0–10)
Secondary outcomes
• Pain intensity difference (VAS 0–10)
• Total pain relief (NRS 0–10)
• Time-weighted-sum of anxiety (SAID24) (NRS 0–10)
• Mood level (NRS 0–10)
• Sedation level (NRS 0–10)
• Adverse effects
• Participant satisfaction (NRS 0–4)
Notes Sources of funding: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Comment: not applicable, crossover trial.
De Franceschi 2016  (Continued)
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Allocation concealment
(selection bias)
Unclear risk Comment: insufficient information.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: "data were collected by blinded physicians and nurses."
Comment: insufficient information.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "data were collected by blinded physicians and nurses."
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: all participants were accounted for from randomization through al-
location, results and follow-up.
Selective reporting (re-
porting bias)
Low risk Comment: study authors reported all of the outcomes planned in their meth-
ods.
Size High risk Comment: total participants 20, < 50 participants per treatment arm.
Other bias Low risk Comment: we found no other potential sources of bias.
De Franceschi 2016  (Continued)
 
 
Methods Allocation: randomized
Controlled: active comparator
Blinding: double-blind
Arm: 2-arm, parallel treatment groups
Centre: single centre
Study duration: not reported
Participants Inclusion criteria: adults aged 18–65 years with SCD treated in the emergency department
Exclusion criteria: history of drug or alcohol abuse; opioid tolerance; hypersensitivity; allergy to mor-
phine or butorphanol; pregnancy; breastfeeding; acute myocardial infarction within 6 months; daily
use of narcotic analgesic during the last week
Baseline characteristics
N: 18 participants
Gender: F 6, M 12
Age (mean): 29.3 (SD 7.7) years
Number randomized: 9 butorphanol; 9 morphine
Number completed: 9 butorphanol; 9 morphine
Setting and location: primary emergency department, Medical College of Virginia Hospital, USA
Interventions Duration of treatment: not explicitly stated
Follow-up period: not explicitly stated
Gonzalez 1988 
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Treatment group (9 participants; 12 VOC episodes):
• IM butorphanol 2 mg, repeated within 30–60 minutes if needed until initial pain relief obtained. Dose
repeated every 2–4 hr to maintain a pain relief rating of ≤ 50 mm until discharge
Control group (9 participants; 12 VOC episodes):
• IM morphine 6 mg, repeated within 30–60 minutes if needed until initial pain relief obtained. Dose
repeated every 2–4 hr to maintain a pain relief rating of ≤ 50 mm until discharge
Standard treatments to all groups: dextrose 5% and 0.45% saline IV infusion 150 mL/hr
Cointerventions: IM prochlorperazine 5–10 mg as needed for nausea or vomiting
Cointerventions/additional analgesia: standard IV hydration
Outcomes Primary outcomes
• Pain (LAS, VAS)
Secondary outcomes
• Global assessment of treatment as decided by nurse
• Level of alertness
• Vital signs
Notes Sources of funding: supported by a grant from Bristol-Meyers United States Pharmaceutical Group,
Evansville, IN, USA.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "patients were randomly assigned on each visit to receive either 2 mg
IM butorphanol or 6 mg IM morphine."
Allocation concealment
(selection bias)
Unclear risk Comment: no technical details of allocation concealment.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "the patient and the medical and nursing sta# were blinded to the
identity of the assigned drug."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "the patient and the medical and nursing sta# were blinded to the
identity of the assigned drug"
Comment: nursing sta# made patient assessments, so likely to be adequate.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: all participants were accounted for from randomization, through
treatment, to follow-up. However, see 'Size' and 'Other Bias' domains below.
Selective reporting (re-
porting bias)
Low risk Comment: no protocol available, but all planed outcomes were reported in re-
sults.
Size High risk Comment: total 18 participants (45 events), some randomized twice, < 50 par-
ticipants per treatment arm.
Other bias High risk Comment: unit of analysis issue, 12 events per treatment arm. However, unit
of randomization was the painful crisis (45 randomized crises events among 18
Gonzalez 1988  (Continued)
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participants), random-effects analysis took this unit of analysis issue appropri-
ately into account.
Gonzalez 1988  (Continued)
 
 
Methods Allocation: randomized
Controlled: placebo
Blinding: double-blind
Arm: 2-arm, parallel-group design
Centre: single centre
Study Duration: unclear
Participants Inclusion criteria: aged ≥ 15 years, people with SCD admitted to emergency department with pain of
VOC
Exclusion criteria: active peptic ulcer disease; systemic bleeding disorders; impaired renal function
(urea > 20 mg/dL /or serum creatinine > 1 mg/dL, or both); other medical condition; history of hyper-
sensitivity to NSAIDs; pregnant women
Baseline characteristics
N: 21 participants; 21 VOC episodes
Gender: F 10, M 11
Age (range): 19–41 years
Number randomized: 10 intervention; 11 control
Number completed: 9 intervention; 9 control
Setting and location: Howard University Hospital, Washington, DC, USA
Interventions Treatment group (10 participants; 10 VOC episodes):
• loading dose ketorolac 30 mg
• continuous IV infusion ketorolac 120 mg, 5 mg/hr, total dose 150 mg on the first day, then maximum
120 mg/day for up to 5 days
Control group (11 participants; 11 VOC episodes):
• loading dose saline
• continuous IV infusion saline, dose each/hr, for up to 5 days
Duration of treatment: duration of crisis, 5-day infusion period
Follow-up period: not stated
Cointerventions/additional analgesia: supplemental IM meperidine 100 mg as needed, frequency no
more than 3 hr
Outcomes Primary outcomes
• Quantity of meperidine required over 5-day period
Secondary outcomes
Perlin 1994 
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• Pain intensity Verbal Categorical Scale, VAS (0–100, Pain Relief Verbal Scale (0–4))
• Duration of hospital stay (measured from the day of enrolment to the day of discharge)
• Global Assessment (1–5: 1 = much worse, 5 = much better)
• Adverse events
Notes Sources of funding: supported in part by a grant from Syntex Research, a division of Syntex (USA), Inc,
who manufacture ketorolac as Toradol
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "the study was randomized," "The study drugs were prepared by a des-
ignated hospital pharmacist (J.P.) and allocated according to a predetermined,
computer generated random code, balanced in blocks of four."
Allocation concealment
(selection bias)
Low risk Comment: preparations by a hospital pharmacist, not study investigators.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "the study drugs were prepared by a designated hospital pharmacist
(J.P.) and allocated according to a predetermined, computer generated ran-
dom code, balanced in blocks of four."
Comment: not explicitly stated, but likely that investigators remained blinded
to treatment allocation.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment: not explicitly stated, but likely that investigators remained blinded
to treatment allocation.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: "3 participants withdrawn prematurely (1-active, 2-control)...ITT analy-
sis to account for withdrawals."
Comment: effect not likely to be small, but appropriate ITT analysis to cope
with withdrawals.
Selective reporting (re-
porting bias)
Low risk Comment: no protocol available, but all planned outcomes were reported in
results
Size High risk Comment: total participants 21, fewer than 50 participants per treatment
arm.
Other bias Low risk Comment: no other potential sources of bias. General comment: ITT analysis
performed.
Perlin 1994  (Continued)
 
 
Methods Allocation: randomized
Controlled: placebo
Blinding: double-blind
Arm: 2-arm, parallel-group design
Centre: multicentre (3 centres)
Qari 2007 
Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
44
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study duration: 48 months
Participants Inclusion criteria: participants aged ≥ 12 years with acute SCD/SCA crisis and no other complica-
tions; pain severe enough to require more than paracetamol; SCA participants with homozygous sick-
le cell (SS) disease; participants admitted through the emergency department with painful VOC severe
enough to require narcotic analgesia
Exclusion criteria: presence of medical or surgical contraindication to LMWH; pregnancy; low platelet
counts (< 100,000/dL) or impaired haemostasis on admission in the form of INR > 1.4 or prolonged aPTT
> 5 seconds of the hospital normal range; complicated SCA; history of cerebrovascular accident; cur-
rent aplasia; acute chest syndrome; exchange transfusion; sequestration; anticoagulants therapy for
other aetiology; participants with painful crises within the month before this admission; women receiv-
ing hormonal contraception
Baseline characteristics
N: 253 participants; 253 VOC episodes
Gender: F 132, M 121
Age (mean): 22.8 (SD 4.5) years intervention; 21.6 (SD 3.8) years control
Number randomized: 127 intervention; 126 control
Number completed: 127 intervention; 126 control
Setting and location: King Abdulaziz University Hospital, King Abdulaziz Oncology Centre, Jeddah,
Saudi Arabia
Interventions Treatment group (127 participants; 127 VOC episodes):
• subcutaneous tinzaparin 175 IU/kg, once daily, for 7 days
Control group (126 participants; 126 VOC episodes):
• subcutaneous placebo, once daily, for 7 days
Duration of treatment: 7 days
Follow-up period: not reported
Cointerventions/additional analgesia: (preintervention) supportive analgesia: IV morphine 1 mg/hr +
hydration IV fluids
Outcomes Primary outcomes
• Total number of hospitalized days
Secondary outcomes
• Rate of decline of the pain intensity over study days
• Number of days experienced with severest/highest pain score (NPS)
• Occurrence of complications during hospitalization
Notes Sources of funding: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "patients were randomized consecutively into either study group."
Comment: no method of randomization provided.
Qari 2007  (Continued)
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Allocation concealment
(selection bias)
Unclear risk Comment: no technical details of allocation concealment provided.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: "Tinzaparin and placebo were provided by the manufacturer. All drug
supplies were appropriately packaged, labelled, and kept in a locked, safe area
under appropriate storage conditions with access limited to persons autho-
rized by the investigator and those who directly involved in the study."
Comment: no technical details.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: no technical details.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: insufficient information, not reported on withdrawals or treatment
failures.
Selective reporting (re-
porting bias)
High risk Comment: no available protocol, some outcomes listed in the methods were
not reported in the results: adverse effects, opioid consumption.
Size Unclear risk Comment: total participants 253, 50 to 199 participants per treatment arm.
Other bias Low risk Comment: no other possible sources of bias.
Qari 2007  (Continued)
 
 
Methods Allocation: randomized
Controlled: active comparator
Blinding: double-blind
Arm: 2-arm, parallel-group design
Centre: single centre
Study duration: not reported
Participants Inclusion criteria: participants presenting to emergency department with acute painful crisis of SCD
Exclusion criteria: not reported
Baseline characteristics
N: 106 participants; 106 VOC episodes
Gender: not reported in abstract
Age: not reported
Number randomized: 54 intervention; 52 control
Number completed: not reported
Setting and location: King Abdulaziz Hospital, Al Ahsa, Saudi Arabia
Interventions Treatment group (54 participants; 54 VOC episodes):
• single IV morphine 0.1 mg/kg
Rehmani 2013 
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Control group (52 participants; 52 VOC episodes):
• single IV paracetamol 1 g
Duration of treatment: duration of painful crisis
Follow-up period: not reported
Cointerventions/additional analgesia: rescue analgesics
Outcomes Primary outcomes
• Pain intensity (VAS 100 mm)
• Pain intensity (VRS 1–4)
• Change in pain intensity after 30 minutes
Secondary outcomes
• Rescue analgesia (morphine)
• Adverse effects
Notes Sources of funding: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "106 patients were randomised to treatment, morphine or paraceta-
mol."
Comment: no clear method of randomization.
Allocation concealment
(selection bias)
Unclear risk Comment: insufficient information.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: insufficient information.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: insufficient information.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: insufficient information.
Selective reporting (re-
porting bias)
High risk Comment: not all outcomes listed in methods were reported in the results,
e.g. VRS; however, unclear due to abstract only.
Size Unclear risk Comment: total participants 106, 50–199 participants per treatment arm.
Other bias Low risk Comment: no other possible sources of bias.
Rehmani 2013  (Continued)
 
 
Methods Allocation: randomized
Wright 1992 
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Controlled: placebo
Blinding: double-blind
Arm: 2-arm, parallel-group trial (single dose)
Centre: multicentre
Study duration: 10 months
Participants Inclusion criteria: men and women presenting to emergency department with chief complaint of crisis
pain, must have self-rated moderate or severe pain intensity on a categorical scale
Exclusion criteria: allergy to study drugs; active peptic ulcer; bleeding disorders; analgesics or central
nervous system-active drugs during the 3-hr period before administration of study medication
Baseline characteristics
N: 18 participants; 24 events
Gender: F 15, M 9
Age (mean): 29.8 years intervention; 31.9 years control
Number randomized: 12 events intervention; 12 events control
Number completed: unclear
Setting and location: Vanderbilt University Hospital or Metropolitan Nashville General Hospital, USA
Interventions Treatment group (12 VOC episodes):
• IM ketorolac 60 mg
Control group (12 VOC episodes):
• IM saline placebo
Duration of treatment: 4 hr
Follow-up period: not reported
Cointerventions/additional analgesia: both groups received IV meperidine 50 mg and IV promet-
hazine 12.5 mg on presentation and a standardized dose of meperidine every 30 minutes during 4-hr
observation.
Outcomes Primary outcomes
• Pain intensity (VAS 100 mm)
Secondary outcomes
• Pain intensity on categorical scale – mild, moderate, severe
• 40% reduction in total narcotic requirement over 4 hr
• Total relief pain score: 240 minutes – baseline scores
Notes Sources of funding: study was supported by Biomedical Research Support Grant RR-05424.
Risk of bias
Bias Authors' judgement Support for judgement
Wright 1992  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk Quote: "the study medication was assigned in accordance with a comput-
er-generated randomization schedule, and the drugs were administered in
identical syringes."
Allocation concealment
(selection bias)
Low risk Quote: "patients were enrolled in a prospective double-blind fashion. They
were randomly assigned to receive either ketorolac 60 mg IM or saline placebo
IM."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "the drugs were administered in identical syringes."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "a single nurse observer was responsible for all data collection and
drug administration for all enrolled patients."
Comment: unclear role and knowledge of the study drugs.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: all participants were accounted for from randomization, through
intervention, to follow-up.
Selective reporting (re-
porting bias)
Low risk Comment: all planned outcomes in the methods were reported in the results.
Size High risk Comment: total participants 18, 12 events per treatment arm, < 50 partici-
pants per treatment arm.
Other bias Low risk Comment: no other possible source of bias.
Wright 1992  (Continued)
aPTT: partial thromboplastin time bleeding test; CPS: categorical pain score; F: female; hr: hour; IM: intramuscular; INR: international
normalized ratio; ITT: intention to treat; IV: intravenous; LAS: lung allocation score; LMWH: low-molecular-weight heparin; M: male; NSAID:
non-steroidal anti-inflammatory drugs; N: number of sample size; NPS: numerical pain score; NRS: numerical rating scale; SB/Thal: sickling
beta-thalassaemia; SCA: sickle cell anaemia; SCD: sickle cell disease; SD: standard deviation; SPID24: sum of the pain intensity di#erence
in 24 hours; VAS: visual analogue scale; VOC: vaso-occlusive crisis; VRS: verbal rating scale.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Al-Jam'a 1999 Participants: children and adults aged ≥ 2.5 years. Age data not reported separately.
Ataga 2018 Participants: VOC (crisis event) as an outcome, not the condition/population.
Ballas 2010 Outcomes: did not report on pain as an outcome as per eligibility criteria.
Cho 2016 Intervention: patient-controlled analgesia.
Dampier 2010 Participants: aged ≥ 10 years, no separate data reported for ≥ 18 years (no full-text publication
available).
Dampier 2013 Study design: not double-blind (single blind with participants knowing the treatment and asses-
sors blinded).
Notes: terminated early due to low accrual.
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Study Reason for exclusion
Desai 2013 Outcomes: did not report on pain as an outcome as per eligibility criteria.
Euctr 2008 Intervention: patient-controlled analgesia.
Euctr 2011 Participants: paediatric population aged < 18 years.
Gonzalez 1991 Intervention: patient-controlled analgesia.
Isrctn 2006 Intervention: patient-controlled analgesia.
Isrctn 2009 Participants: paediatric population aged < 18 years.
Morris 2009 Participants: paediatric population aged < 18 years (age range 3–19 years).
Nct 2019a Participants: paediatric population aged < 18 years.
Nct 2019b Study design: open-label study design, not blinded as per eligibility criteria.
Niihara 2018 Participants: VOC (crisis event) as an outcome, not the condition/population.
Orringer 2001 Participants: children and adults (age range 8–60 years). Pain data available for < 15 years but not
adults.
Pactr 2018 Study design: open-label trial, not blinded as per eligibility criteria.
Puri 2019 Participants: paediatric population aged 1-21 years. No separate data available for 18-21 years in
the full-text publication.
Rousseau 2015 Participants: paediatric population (age range 6–21 years).
Sandoval 2013 Study design: open-label case series, no evidence of controls or randomization. Not a randomized
controlled trial.
Shah 2019 Participants: VOC (crisis event) as an outcome, not the condition/population.
Smith 2011 Intervention: patient-controlled analgesia.
Tanabe 2018 Study design: open-label trial, not blinded as per inclusion criteria.
Telen 2015 Participants: 54 adults, 20 children. Data not reported separately.
Uzun 2010 Study design: not double-blind as per eligibility criteria.
van Beers 2007 Intervention: patient-controlled analgesia.
VOC: vaso-occlusive crisis.
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Allocation: randomized
Controlled: placebo
Blinding: double-blind
De Castro 2013 
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Arm: 2-arm parallel group
Centre: multicentre
Study dates and duration: not reported
Participants Diagnostic criteria/inclusion criteria: people hospitalized for VOC
Exclusion criteria: not reported in abstract
Number: not reported in abstract
Age: 12–60 years
Gender: not reported
Setting of recruitment and treatment: not reported in abstract
Country and sites: not reported in abstract
Interventions Treatment group (number not reported): multiple IV doses of GMI 1070
Loading dose to achieve steady state drug level was followed by maintenance doses every 12 hr.
Study dose was doubled per protocol after interim pharmacokinetic analysis.
Control group (number not reported): not reported in abstract
Outcomes Primary
• VAS pain intensity (10 cm)
Secondary
• Time to resolution of VOC
• Opioid utilization
Notes Conference abstract only. Insufficient data to analyse. Attempted to contact authors.
De Castro 2013  (Continued)
 
 
Methods Allocation: randomized by unclear method
Controlled: placebo
Blinding: double-blind
Participants Number: not reported
Age: not reported
Gender: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Interventions Study period: 5 days
Both groups: IM meperidine or hydroxyzine (or both), dose not reported, every 3–4 hr as needed.
Intervention group (number not reported): oral diflunisal 1000 mg loading dose + oral diflunisal
500 mg every 12 hr
Perlin 1988 
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Control group (number not reported): oral placebo, loading dose + oral placebo, every 12 hrs
Outcomes Primary
• Pain score according to a categorical pain scale
Notes Conference abstract only. Insufficient data to analyse. Attempted to contact authors
Perlin 1988  (Continued)
 
 
Methods Allocation: randomized by unclear method
Controlled: placebo
Blinding: not reported
Arm: 2-arm, parallel group
Centre: single
Study duration: not reported
Participants Inclusion criteria: not reported
Exclusion criteria: not reported
Baseline characteristics
36 participants
Gender: not reported in abstract
Ages: not reported in abstract
Number randomized: not reported
Number completed: not reported
Setting and location: rural hospital, Togo, West Africa
Interventions Duration of treatment: not reported
Follow-up period: not reported
Treatment group (number not reported): not reported
Control group (number not reported): placebo not reported
Cointerventions/additional analgesia: not reported
Outcomes Primary: not reported
Secondary: not reported
Notes Unclear from abstract whether the study reported on pain as an outcome as per eligibility criteria.
Teuscher 1989 
hr: hour; IM: intramuscular; IV: intravenous; VAS: visual analogue scale; VOC; vaso-occlusive crisis.
 
Characteristics of ongoing studies [ordered by study ID]
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Trial name or title To relieve crisis pain in sickle cell anemia patients
Methods Allocation: randomized
Controlled: active comparator
Blinding: double-blind
Arm: 2 parallel
Centre: single
Study duration: February 2017 (recruited, ongoing, data not published)
Participants Inclusion criteria: adults with sickle cell anemia; no prior history of cardiovascular or respiratory
disease; no hypertension; not using other analgesic drugs
Exclusion criteria: known major side effects of trial medications; addiction, especially to mor-
phine
Baseline characteristics
N: target sample size 84, recruitment complete
Gender: female and male
Ages: no age limit (if included, need separate adult data only)
Setting and location: Emam Reza Hospital, Mashhad University of Medical Sciences, Iran
Interventions Treatment group: 30 mg injection ketorolac
Control group: 4-10 mg injection morphine at 4 to 5 ml injection water solution
Outcomes Primary outcomes
• Pain relief (VAS) 5 minutes before and 5 minutes after injection
Secondary outcomes
• Side effects
Starting date 19 February 2017
Contact information Somaye Sadat Hosseiny, Emam Reza Hospital, Emam Reza Square, Ebne Sina Avenue Mshhad Iran
Email: somaye_2004a@yahoo.com
Notes If study is included in future updates, need to separate adult data only
IRCT2016072511956N6 
 
 
Trial name or title Ketamine for acute painful crisis in sickle cell disease patients
Methods Allocation: randomized
Controlled: active comparator
Blinding: triple
Arm: 3 arm, parallel groups
NCT03431285 
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Centre: single
Study duration: 1 January 2018 (recruiting, ongoing)
Participants Inclusion criteria: known diagnosis of sickle cell disease based on sickle cell tests and haemoglo-
bin electrophoresis; acute onset of painful crises, defined as having an onset within 7 days
Exclusion criteria: healthy volunteers; other comorbidities; allergies to study medication; preg-
nancy or breastfeeding
Baseline characteristics
N: 264 participants, still recruiting
Gender: men and women
Ages: 18–60 years
Setting and location: Dammam University, Saudi Arabia
Interventions Treatment group: morphine
Control group: ketamine
Other group: standard intravenous hydration
Outcomes Primary outcomes
• Pain
Secondary outcomes
• Length of stay in emergency department
• Cumulative use of opioids
• Rate of hospital admission
• Adverse effects
Starting date 1 January 2018
Contact information Mohammed SS Alshahrani, MD, Dammam, Eastern, Saudi Arabia, 31952
Notes  
NCT03431285  (Continued)
 
 
Trial name or title Dronabinol for pain and inflammation in adults living with sickle cell disease
Methods Allocation: randomized
Controlled: placebo
Blinding: double-blind
Arm: 2 crossover
Centre: single
Study duration: June 2019 (recruiting). Estimated completion June 2020.
NCT03978156 
Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
54
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Participants Inclusion criteria: adults over 18 clinical diagnosis of SCD; baseline score <60 ACQ-Me 7-day pain
domain
Exclusion criteria: intolerance to dronabinol, sesame oil, or marijuana; psychiatric disorder; con-
comitant medical condition; pregnant
Baseline characteristics
N: 30
Gender: female and male
Ages: 18 years or older
Setting and location: Yale New Haven Hospital, USA
Interventions Treatment group: 2.5 mg dronabinol oral tablet (titrated to 10 mg twice daily)
Control group: placebo oral tablet
Outcomes Primary outcomes
• Feasibility
• Adherence to study medication and study procedures
• Avoidance of other cannabinoid substances
Secondary outcomes
• Patient reported 7-day pain interference (Adult Sickle Cell Quality of Life Measurement Informa-
tion System ASCQ-Me)
• Patient reported emotional impact (Adult Sickle Cell Quality of Life Measurement Information Sys-
tem ASCQ-Me)
• Patient reported sleep impact (Adult Sickle Cell Quality of Life Measurement Information System
ASCQ-Me)
• Patient reported stiffness impact (Adult Sickle Cell Quality of Life Measurement Information Sys-
tem ASCQ-Me)
• Patient reported social functioning (Adult Sickle Cell Quality of Life Measurement Information Sys-
tem ASCQ-Me)
• Pain severity (Numerical Rating Scale 0-10)
• Nociceptive Pain Severity (Patient Reported Outcomes Measurement Information System
PROMIS)
• Neuropathic Pain Severity (Patient Reported Outcomes Measurement Information System
PROMIS)
• Gastrointestinal Nausea short form (Patient Reported Outcomes Measurement Information Sys-
tem PROMIS)
• Emotional distress anxiety 8a (Patient Reported Outcomes Measurement Information System
PROMIS)
• Opioid utilization
• Markers of inflammation: white blood cell count, C-reactive protein, serum tryptase, serum pro-
inflammatory cytokines, serum measure of Substance P
Starting date 6 June 2019
Contact information Susanna Curtis, Yale New Haven Hospital Smilow Cancer Centre, New Haven, Connecticut, 06510,
USA. Yale University School of Medicine Oncology Section. Email: susanna.curtis@yale.edu
Notes  
NCT03978156  (Continued)
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mg: milligrams; ml: millilitres; N: number of participants; SCD: sickle cell disease; VAS: visual analogue scale
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Non-steroidal anti-inflammatory drugs (NSAIDs) versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Patient Global Impression of Change
very much improved
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not select-
ed
1.1 Ketorolac 30 mg bolus + 120 mg IV
vs placebo bolus + IV
1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Patient Global Impression of Change
much or very much improved
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not select-
ed
2.1 Ketorolac 30 mg bolus + 120 mg IV
vs placebo bolus + IV
1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Opioid consumption 3   Std. Mean Difference (IV, Fixed, 95% CI) Totals not select-
ed
3.1 Ketoprofen 300 mg IV + 100 mg oral
vs saline IV + oral
1   Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Ketorolac 30 mg bolus + 120 mg IV
vs placebo bolus + IV
1   Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Ketorolac 60 mg IM vs saline IM 1   Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Time to pain resolution (hours) 1   Mean Difference (IV, Fixed, 95% CI) Totals not select-
ed
4.1 Ketoprofen 300 mg IV + 100 mg oral
vs saline IV + oral
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 1.1.   Comparison 1 Non-steroidal anti-inflammatory drugs (NSAIDs) versus
placebo, Outcome 1 Patient Global Impression of Change very much improved.
Study or subgroup NSAIDs Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
1.1.1 Ketorolac 30 mg bolus + 120 mg IV vs placebo bolus + IV  
Perlin 1994 3/10 0/11 7.64[0.44,131.75]
Favours NSAIDs 1000.01 100.1 1 Favours placebo
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Analysis 1.2.   Comparison 1 Non-steroidal anti-inflammatory drugs (NSAIDs) versus
placebo, Outcome 2 Patient Global Impression of Change much or very much improved.
Study or subgroup NSAIDs Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
1.2.1 Ketorolac 30 mg bolus + 120 mg IV vs placebo bolus + IV  
Perlin 1994 6/10 4/11 1.65[0.65,4.19]
Favours NSAIDs 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.3.   Comparison 1 Non-steroidal anti-inflammatory
drugs (NSAIDs) versus placebo, Outcome 3 Opioid consumption.
Study or subgroup NSAIDs Placebo Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.3.1 Ketoprofen 300 mg IV + 100 mg oral vs saline IV + oral  
Bartolucci 2009 33 110 (74.1) 33 88 (105) 0.24[-0.25,0.72]
   
1.3.2 Ketorolac 30 mg bolus + 120 mg IV vs placebo bolus + IV  
Perlin 1994 9 1866.7 (1112.4) 11 2804.5 (795.1) -0.95[-1.89,-0.01]
   
1.3.3 Ketorolac 60 mg IM vs saline IM  
Wright 1992 12 231 (92) 12 250 (85) -0.21[-1.01,0.6]
Favours NSAIDs 10050-100 -50 0 Favours placebo
 
 
Analysis 1.4.   Comparison 1 Non-steroidal anti-inflammatory drugs
(NSAIDs) versus placebo, Outcome 4 Time to pain resolution (hours).
Study or subgroup NSAIDs Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.4.1 Ketoprofen 300 mg IV + 100 mg oral vs saline IV + oral  
Bartolucci 2009 33 51 (25.7) 33 50 (33.1) 1[-13.3,15.3]
Favours NSAIDs 10050-100 -50 0 Favours placebo
 
 
A P P E N D I C E S
Appendix 1. Database search strategies
CENTRAL search strategy (via CRSO)
#1 MeSH DESCRIPTOR Anemia, Sickle Cell EXPLODE ALL TREES
#2 (sickle cell):TI,AB,KY
#3 "SCD":TI,AB,KY
#4 ("sickling disorder"):TI,AB,KY
#5 "HBS":TI,AB,KY
#6 ((haemoglobin near1 disease)):TI,AB,KY
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#7 ((haemoglobin near1 disease)):TI,AB,KY
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 30
#9 MeSH DESCRIPTOR Pain EXPLODE ALL TREES
#10 pain*:TI,AB,KY
#11 #9 OR #10
#12 ((acetaminophen or "acetylsalicylic acid" or "alendronic acid" or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or "choline magnesium trisalicylate" or clonazepam or
clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or diazepam
or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone or "hyoscine
hydrobromide" or ibuprofen or ketamine or ketoprofen or ketorolac or "levo bupivacaine" or lidocaine or loperamide or lorazepam or
mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous oxide or nortriptyline
or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or "phenytoin" or piroxicam or
pregabalin or propoxyphene or "risedronate sodium" or "sodium clodronate" or tetracaine or tramadol or "valproic acid")):TI,AB,KY
#13 MeSH DESCRIPTOR Analgesics EXPLODE ALL TREES
#14 MeSH DESCRIPTOR Anesthesia, Local
#15 MeSH DESCRIPTOR Anti-Inflammatory Agents, Non-Steroidal EXPLODE ALL TREES
#16 #12 OR #13 OR #14 OR #15
#17 #8 AND #11 AND #16
MEDLINE search strategy (via Ovid)
1 exp Anemia, Sickle Cell/
2 sickle cell.tw.
3 "SCD".tw.
4 "sickling disorder".tw.
5 "HBS".tw.
6 (hemoglobin adj1 disease).tw.
7 (haemoglobin adj1 disease).tw.
8 or/1-7
9 exp Pain/
10 pain*.tw.
11 or/9-10
12 (acetaminophen or "acetylsalicylic acid" or "alendronic acid" or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or "choline magnesium trisalicylate" or clonazepam or
clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or diazepam
or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone or "hyoscine
hydrobromide" or ibuprofen or ketamine or ketoprofen or ketorolac or "levo bupivacaine" or lidocaine or loperamide or lorazepam or
mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous oxide or nortriptyline
or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or "phenytoin" or piroxicam or
pregabalin or propoxyphene or "risedronate sodium" or "sodium clodronate" or tetracaine or tramadol or "valproic acid").tw.
13 exp Analgesics/
14 Anesthesia, Local/
15 exp Anti-Inflammatory Agents, Non-Steroidal/
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16 or/12-15
17 8 and 11 and 16
18 randomized controlled trial.pt.
19 controlled clinical trial.pt.
20 randomized.ab.
21 placebo.ab.
22 drug therapy.fs.
23 randomly.ab.
24 trial.ab.
25 groups.ab.
26 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
27 exp animals/ not humans.sh.
28 26 not 27
29 17 and 28
Embase search strategy (via Ovid)
1 exp Anemia, Sickle Cell/
2 sickle cell.tw.
3 "SCD".tw.
4 "sickling disorder".tw.
5 "HBS".tw.
6 (hemoglobin adj1 disease).tw.
7 (haemoglobin adj1 disease).tw.
8 or/1-7
9 exp Pain/
10 pain*.tw.
11 or/9-10
12 (acetaminophen or "acetylsalicylic acid" or "alendronic acid" or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or "choline magnesium trisalicylate" or clonazepam or
clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or diazepam
or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone or "hyoscine
hydrobromide" or ibuprofen or ketamine or ketoprofen or ketorolac or "levo bupivacaine" or lidocaine or loperamide or lorazepam or
mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous oxide or nortriptyline
or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or "phenytoin" or piroxicam or
pregabalin or propoxyphene or "risedronate sodium" or "sodium clodronate" or tetracaine or tramadol or "valproic acid").tw.
13 exp Analgesics/
14 Anesthesia, Local/
15 exp Anti-Inflammatory Agents, Non-Steroidal/
16 or/12-15
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17 8 and 11 and 16
18 Randomized controlled trial/
19 Controlled clinical study/
20 18 or 19
21 Random$.ti,ab.
22 randomization/
23 intermethod comparison/
24 placebo.ti,ab.
25 (compare or compared or comparison).ti.
26 ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab.
27 (open adj label).ti,ab.
28 ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab.
29 double blind procedure/
30 parallel group$1.ti,ab.
31 (crossover or cross over).ti,ab.
32 ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or participant
$1)).ti,ab.
33 (assigned or allocated).ti,ab.
34 (controlled adj7 (study or design or trial)).ti,ab.
35 (volunteer or volunteers).ti,ab.
36 human experiment/
37 trial.ti.
38 or/20-37
39 17 and 38
LILACS search strategy (via BIRME)
(sickle cell) or SCD or (sickling disorder) or HBS or (haemoglobin disease) or (haemoglobin disease) [Words] and pain$ [Words] and
(acetaminophen or (acetylsalicylic acid) or (alendronic acid) or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or (choline magnesium trisalicylate) or clonazepam or
clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or diazepam
or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone or (hyoscine
hydrobromide) or ibuprofen or ketamine or ketoprofen or ketorolac or (levo bupivacaine) or lidocaine or loperamide or lorazepam or
mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous oxide or nortriptyline
or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or (phenytoin) or piroxicam or
pregabalin or propoxyphene or (risedronate sodium) or (sodium clodronate) or tetracaine or tramadol or (valproic acid)) [Words]
Appendix 2. Primary outcome data
 
Study Treatment Partici-
pant-re-
ported
pain re-
Partici-
pant-re-
ported
pain re-
Patient Glob-
al Impression
of Change:
both 'much
Additional pain data report-
ed by study
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lief of
50% or
greater
lief of
30% or
greater
improved'
& 'much or
very much
improved'
VAS (1–10); mean (% decrease
from arrival)
At arrival
Ketamine: 8.7 (95% CI 8.07 to
9.29)
Placebo: 8.5 (95% CI 7.90 to
9.05)
At administration
Ketamine: 6.0 (95% CI 4.71, to
7.29); 31%
Placebo: 7.0 (95% CI 6.20 to
7.85); 17.6%
Aram-
basik 2013
Treatment group (17 participants; 17
VOC episodes):
• IV hydromorphone 2 mg
• 15 min later: IV hydromorphone 2 mg
+ IV ketamine 6.2 mg/kg
Control group (20 participants; 20
VOC episodes):
• IV hydromorphone 2 mg
• 15 min later: IV hydromorphone 2 mg
+ IV saline placebo
Ketamine:
no data
Placebo:
no data
Ketamine:
no data
Placebo:
no data
Ketamine: no
data
Placebo: no
data
At disposition
Ketamine: 5.2 (95% CI 4.01 to
6.46); 40.2%
Placebo: 5.6 (95% CI 4.27 to
6.93); 34.1%
CPS (0–3) daily mean scores;
median
Ketoprofen: 0.4 (IQR 0.2–0.7)
Placebo: 0.4 (IQR 0.2–0.7)
Bartolucci
2009
Ketoprofen (33 VOC episodes):
Days 1 and 2: continuous IV ketoprofen
infusion, 300 mg/day, 2 days
Days 3–5: oral ketoprofen 100 mg, every
8 hr, 3 days
Placebo (33 VOC episodes):
Days 1 and 2: physiological saline con-
tinuous IV infusion, 2 days.
Days 3–5: oral placebo tablet, every 8 hr,
3 days
Ketopro-
fen: no
data
Placebo:
no data
Ketopro-
fen: no
data
Placebo:
no data
Ketoprofen:
no data
Placebo: no
data
VAS (0–100) daily mean
scores;median
Ketoprofen: 12.6 (IQR 4.8–23.2)
Placebo: 9.6 (IQR 5.8–33.2)
Benjamin
1986
Cetiedil 0.2 (16 participants; 16 VOC
episodes): 0.2 mg/kg IV infusion, every
8 hr, 4 days, total 12 doses
Cetiedil 0.3 (18 participants; 18 VOC
episodes): 0.3 mg/kg IV infusion, every
8 hr, 4 days, total 12 doses
Cetiedil 0.4 (13 participants; 13 VOC
episodes): 0.4 mg/kg IV infusion, every
8 hr, 4 days, total 12 doses
Placebo (16 participants; 16 VOC
episodes): saline IV infusion, every 8 hr,
4 days, total 12 doses
Cetiedil
0.2 mg: no
data
Cetiedil
0.3 mg: no
data
Cetiedil
0.4 mg: no
data
Placebo:
no data
Cetiedil
0.2 mg: no
data
Cetiedil
0.3 mg: no
data
Cetiedil
0.4 mg: no
data
Placebo:
no data
Overall evalu-
ation of treat-
ment (good)
Cetiedil 0.2
mg: 5/16
Cetiedil 0.3
mg: 4/18
Cetiedil 0.4
mg: 4/13
Placebo: 2/16
Cetiedil 0.2 mg: no data
Cetiedil 0.3 mg: no data
Cetiedil 0.4 mg: no data
Placebo: no data
  (Continued)
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Overall evalu-
ation of treat-
ment (good +
excellent)
Cetiedil 0.2
mg: 9/16
Cetiedil 0.3
mg: 10/18
Cetiedil 0.4
mg: 11/13
Placebo: 4/16
At 6 hr
KTM: 0/20
KTMF:
12/20
At 6 hr
KTM: 1/20
KTMF:
20/20
De
Franceschi
2016
Treatment group VOC1 (KTM) (10 par-
ticipants; 20 VOC episodes): continu-
ous IV infusion ketorolac 0.86 mg/kg/
day + tramadol 7.2 mg/kg/day + meto-
clopramide 0.57 mg/kg/day, for maxi-
mum of 72 hr
Treatment group VOC2 (KT MF) (10
participants; 20 VOC episodes): con-
tinuous IV infusion ketorolac 0.86 mg/
kg/day + tramadol 7.2 mg/kg/day +
metoclopramide 0.57 mg/kg/day + fen-
tanyl buccal single tablet 100 μg after 3
hr from beginning of multimodal anal-
gesia, for maximum of 72 hr
At 12 hr
KTM: 4/20
KTMF:
18/20
At 12 hr
KTM: 4/20
KTMF:
20/20
KTM: no data
KTMF: no data
KTM: no data
KTMF: no data
Good
Butorphanol:
47.6%
Morphine:
38.1%
VAS (0–100 mm); adjusted
means overall
Butorphanol: 44.42
Morphine: 46.08
Gonzalez
1988
Butorphanol (9 participants; 12 VOC
episodes): IM butorphanol 2 mg, re-
peated within 30–60 min until pain relief
obtained, repeat every 2–4 hr, until dis-
charge.
Morphine (9 participants; 12 VOC
episodes): IM morphine 6 mg, repeat
within 30–60 min until pain relief ob-
tained, repeated every 2–4 hr, until dis-
charge
Butor-
phanol:
no data
Morphine:
no data
Butor-
phanol:
no data
Morphine:
no data
Excellent
Butorphanol:
19.1%
Morphine:
33.3%
Pain relief (0–100 mm); adjust-
ed means overall
Butorphanol: 43.79
Morphine: 55.50
Perlin
1994
Ketorolac (10 participants; 10 VOC
episodes): ketorolac 30 mg bolus; con-
tinuous IV infusion ketorolac 120 mg, 5
mg/hr, total dose 150 mg (on first day),
maximum 120 mg/day, up to 5 days
Placebo (11 participants; 11 VOC
episodes): bolus saline; continuous IV
infusion saline, up to 5 days
Ketorolac:
no data
Placebo:
no data
Ketorolac:
no data
Placebo:
no data
Better
Ketorolac:
3/10
Placebo: 4/11
VAS (0–100 mm); mean
At baseline
Ketorolac: 77.7 (95% CI 69.1 to
86.2)
Placebo: 79.1 (95% CI 72.1 to
86.0)
At 24 hr
Ketorolac: 58.6 (95% CI 48.6 to
68.5)
  (Continued)
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Placebo: 72.6 (95% CI 62.4 to
82.8)
P < 0.05
Much better
Ketorolac:
3/10
Placebo: 0/11
VCS (0–3); mean
At baseline
Ketorolac: 2.5
Placebo: 2.6
At 24 hr
Ketorolac: 2.0
Placebo: 2.4
Better + much
better
Ketorolac:
6/10
Placebo: 4/11
VRS (0–4) at 24 hr; mean
Ketorolac: 1.8
Placebo: 1.9
Qari 2007 Tinzaparin (127 participants; 127 VOC
episodes): subcutaneous tinzaparin 175
IU/kg, once daily, 7 days
Placebo (126 participants; 126 VOC
episodes): subcutaneous placebo, once
daily, 7 days
Tinza-
parin: no
data
Placebo:
no data
Tinza-
parin: no
data
Placebo:
no data
Tinzaparin: no
data
Placebo: no
data
Tinzaparin: no data
Placebo: no data
Rehmani
2013
Morphine (54 participants; 54 VOC
episodes): IV morphine 0.1 mg/kg, sin-
gle dose
Paracetamol (52 participants; 52 VOC
episodes): IV paracetamol 1 g, single
dose
Morphine:
no data
Paraceta-
mol: no
data
Morphine:
no data
Paraceta-
mol: no
data
Morphine: no
data
Paracetamol:
no data
VAS (0–100 mm) at 30 min;
mean
Morphine: 44 (95% CI 33 to 56)
Paracetamol: 41 (95% CI 32 to
49)
P = 0.72
VAS (0–100 mm) at baseline;
mean
Ketorolac: 70.3
Placebo: 79.3
P = 0.26
Wright
1992
Ketorolac (12 VOC episodes): IM ke-
torolac 60 mg, single dose
Placebo (12 VOC episodes): IM saline,
single dose
Ketorolac:
no data
Placebo:
no data
Ketorolac:
no data
Placebo:
no data
Ketorolac: no
data
Placebo: no
data
VAS (0–100 mm) at 4 hr; mean
Ketorolac: 44 (SD 34)
Placebo: 37 (SD 31)
P = 0.49
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CI: confidence interval; CPS: categorical pain scale; hr: hour; IM: intramuscular; IQR: interquartile range; IV: intravenous; KTM: ke-
torolac + tramadol + metoclopramide; KTMF: ketorolac + tramadol + metoclopramide + fentanyl;min: minute; SD: standard devia-
tion; VAS: visual analogue scale; VCS: visual categorical score; VOC: vaso-occlusive crisis; VRS: verbal rating scale.
  (Continued)
 
Appendix 3. Secondary outcome data
 
Study Treatment Opioid con-
sumption
Time to
pain res-
olution
(hours)
Length
of hospi-
talization
(days)
Tolerance
to opioids
Aram-
basik 2013
Treatment group (17 participants; 17 VOC episodes):
• IV hydromorphone 2 mg
• 15 min later: IV hydromorphone 2 mg + IV ketamine 6.2
mg/kg
Control group (20 participants; 20 VOC episodes):
• IV hydromorphone 2 mg
• 15 min later: IV hydromorphone 2 mg + IV saline placebo
Ketamine: no
data
Placebo: no da-
ta
Ketamine:
no data
Placebo:
no data
Ketamine:
no data
Placebo:
no data
Ketamine:
no data
Placebo:
no data
Bartolucci
2009
Ketoprofen (33 VOC episodes):
Day 1 and 2: continuous IV infusion ketoprofen, 300 mg/
day, 2 days
Days 3–5: 100 mg oral ketoprofen, every 8 hr, 3 days
Placebo (33 VOC episodes):
Day 1 and 2: physiological saline continuous IV infusion, 2
days
Days 3–5: oral placebo tablet, every 8 hr, 3 days
Median, mg
Ketoprofen: 110
(IQR 46–195)
Placebo: 88
(IQR 52.5–
262.5)
Median,
hours
Ketopro-
fen: 51
(IQR 35.5–
87)
Placebo:
50 (IQR
36–103)
Ketopro-
fen: no
data
Placebo:
no data
Ketopro-
fen: no
data
Placebo:
no data
Benjamin
1986
Cetiedil 0.2 (16 participants; 16 VOC episodes): 0.2 mg/
kg IV infusion, every 8 hr, 4 days, total 12 doses
Cetiedil 0.3 (18 participants; 18 VOC episodes): 0.3 mg/
kg IV infusion, every 8 hr, 4 days, total 12 doses
Cetiedil 0.4 (13 participants; 13 VOC episodes): 0.4 mg/
kg IV infusion, every 8 hr, 4 days, total 12 doses
Placebo (16 participants; 16 VOC episodes): saline IV infu-
sion, every 8 hr, 4 days, total 12 doses
Cetiedil 0.2 mg:
no data
Cetiedil 0.3 mg:
no data
Cetiedil 0.4 mg:
no data
Placebo: no da-
ta
P > 0.05
Cetiedil
0.2 mg: no
data
Cetiedil
0.3 mg: no
data
Cetiedil
0.4 mg: no
data
Placebo:
no data
P > 0.05
Cetiedil
0.2 mg: no
data
Cetiedil
0.3 mg: no
data
Cetiedil
0.4 mg: no
data
Placebo:
no data
Cetiedil
0.2 mg: no
data
Cetiedil
0.3 mg: no
data
Cetiedil
0.4 mg: no
data
Placebo:
no data
De
Franceschi
2016
Treatment group VOC1 (KTM) (10 participants; 20 VOC
episodes): continuous IV infusion ketorolac 0.86 mg/kg/
day + tramadol 7.2 mg/kg/day + metoclopramide 0.57 mg/
kg/day, for maximum of 72 hr
KTM: no data
KTMF: no data
KTM: no
data
KTMF: no
data
KTM: no
data
KTMF: no
data
KTM: no
data
KTMF: no
data
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Treatment group VOC2 (KTMF) (10 participants; 20 VOC
episodes): continuous IV infusion ketorolac 0.86 mg/kg/
day + tramadol 7.2 mg/kg/day + metoclopramide 0.57 mg/
kg/day + fentanyl buccal single tablet 100 μg after 3 hr from
beginning of multimodal analgesia, for maximum of 72 hr
Gonzalez
1988
Butorphanol (9 participants; 12 VOC episodes): IM bu-
torphanol 2 mg, repeated within 30–60 min until pain relief
obtained, repeat every 2–4 hr, until discharge
Morphine (9 participants; 12 VOC episodes): IM morphine
6 mg, repeat within 30–60 min until pain relief obtained, re-
peated every 2–4 hr, until discharge
Morphine: no
data
butorphanol:
no data
Butor-
phanol:
no data
Morphine:
no data
Butor-
phanol:
no data
Morphine:
no data
Butor-
phanol:
no data
Morphine:
no data
Meperidine mg
mean total dose
Ketorolac:
1866.7 (SD
1112.4)
Placebo: 2804.5
(SD 795.1)
Perlin
1994
Ketorolac (10 participants; 10 VOC episodes): bolus ke-
torolac 30 mg; continuous IV infusion ketorolac 120 mg, 5
mg/hr, total dose 150 mg (on first day), maximum 120 mg/
day, up to 5 days
Placebo (11 participants; 11 VOC episodes): bolus saline;
continuous IV infusion saline, up to 5 days
Mean daily dose
Ketorolac:
523.6 (SD 222.1)
Placebo: 662.4
(SD 68.6)
Ketorolac:
no data
Placebo:
no data
Ketorolac:
3.3
Placebo:
7.2
P < 0.05
Ketorolac:
no data
Placebo:
no data
Qari 2007 Tinzaparin (127 participants; 127 VOC episodes): subcu-
taneous tinzaparin 175 IU/kg, once daily, 7 days
Placebo (126 participants; 126 VOC episodes): subcuta-
neous placebo, once daily, 7 days
Morphine
Tinzaparin: un-
clear
Placebo: un-
clear
Mean
hours
Tinza-
parin:
61.68
Placebo:
104.4
Mean days
Tinza-
parin: 7.08
Placebo:
12.06
Tinza-
parin: no
data
Placebo:
no data
Rehmani
2013
Morphine (54 participants; 54 VOC episodes): IV mor-
phine 0.1 mg/kg, single dose
Paracetamol (52 participants; 52 VOC episodes): IV
paracetamol 1 g, single dose
Rescue mor-
phine (0.1 mg/
kg) at 30 min:
Morphine:
27/54
Paracetamol:
24/52
Morphine:
no data
Paraceta-
mol: no
data
Morphine:
no data
Paraceta-
mol: no
data
Morphine:
no data
Paraceta-
mol: no
data
Wright
1992
Ketorolac (12 VOC episodes): IM ketorolac 60 mg, single
dose
Placebo (12 VOC episodes): IM saline, single dose
Mean (SD)
meperidine mg
Ketorolac:
231(92)
Placebo:
250(85)
Ketorolac:
no data
Placebo:
no data
Ketorolac:
no data
Placebo:
no data
Ketorolac:
no data
Placebo:
no data
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P = 0.61
CPS: categorical pain scale; hr: hour; IM: intramuscular; IQR: interquartile range; IV: intravenous; KTM: ketorolac + tramadol + meto-
clopramide; KTMF: ketorolac + tramadol + metoclopramide + fentanyl;min: minutes; SD: standard deviation; VAS: visual analogue
scale; VCS: visual categorical score; VOC: vaso-occlusive crisis; VRS: verbal rating scale.
  (Continued)
 
Appendix 4. Adverse events and withdrawals
 
Study Treatment Total number of
participants re-
porting ≥ 1ad-
verse event
Serious
adverse
events
Total all-
cause
with-
drawals
With-
drawals
due to
adverse
events
Aram-
basik 2013
Treatment group (17 participants; 17 VOC episodes):
• IV hydromorphone 2 mg
• 15 min later: IV hydromorphone 2 mg + IV ketamine 6.2
mg/kg
Control group (20 participants; 20 VOC episodes):
• IV hydromorphone 2 mg
• 15 min later: IV hydromorphone 2 mg + IV saline placebo
Ketamine: no da-
ta
Placebo: no data
Ketamine:
no data
Placebo:
no data
Ketamine:
no data
Placebo:
no data
Ketamine:
no data
Placebo:
no data
Bartolucci
2009
Ketoprofen (33 VOC episodes):
Days 1 and 2: continuous IV infusion ketoprofen 300 mg/
day, 2 days
Days 3–5: 100 mg oral ketoprofen, every 8 hr, 3 days
Placebo (33 VOC episodes):
Days 1 and 2: physiological saline continuous IV infusion,
2 days
Days 3–5: oral placebo tablet, every 8 hr, 3 days
Ketoprofen:
16/33
Placebo: 19/33
Ketopro-
fen: 1/33
Placebo:
2/33
Ketopro-
fen: un-
clear
Placebo:
unclear
Ketopro-
fen: 1/33
Placebo:
1/33
Benjamin
1986
Cetiedil 0.2 (16 participants; 16 VOC episodes): 0.2 mg/
kg IV infusion, every 8 hr, 4 days, total 12 doses
Cetiedil 0.3 (18 participants; 18 VOC episodes): 0.3 mg/
kg IV infusion, every 8 hr, 4 days, total 12 doses
Cetiedil 0.4 (13 participants; 13 VOC episodes): 0.4 mg/
kg IV infusion, every 8 hr, 4 days, total 12 doses
Placebo (16 participants; 16 VOC episodes): saline IV in-
fusion, every 8 hr, 4 days, total 12 doses
Cetiedil 0.2 mg:
2/17
Cetiedil 0.3 mg:
9/18
Cetiedil 0.4 mg:
8/14
Placebo: 8/18
"The incidence
of adverse ef-
fects was similar
for the cetiedil
0.3, 0.4 and
placebo groups,
and significant-
ly lower for the
Cetiedil
0.2 mg:
0/16
Cetiedil
0.3 mg:
0/18
Cetiedil
0.4 mg:
0/13
Placebo:
0/16
Cetiedil
0.2 mg:
unclear
Cetiedil
0.3 mg:
unclear
Cetiedil
0.4 mg:
unclear
Placebo:
unclear
Cetiedil
0.2 mg:
unclear
Cetiedil
0.3 mg:
unclear
Cetiedil
0.4 mg:
unclear
Placebo:
unclear
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cetiedil 0.2 group
(p = 0.04). The
most commonly
reported AE were
headache and
nausea and com-
mitting, and dry
mouth."
De
Franceschi
2016
Treatment group VOC1 (KTM) (10 participants; 20 VOC
episodes): continuous IV infusion ketorolac 0.86 mg/kg/
day + tramadol 7.2 mg/kg/day + metoclopramide 0.57
mg/kg/day, for maximum of 72 hr
Treatment group VOC2 (KT MF) (10 participants; 20
VOC episodes): continuous IV infusion ketorolac 0.86 mg/
kg/day + tramadol 7.2 mg/kg/day + metoclopramide 0.57
mg/kg/day + fentanyl buccal single tablet 100 μg after 3 hr
from beginning of multimodal analgesia, for maximum of
72 hr
KTM: 0/20
KTMF: 0/20
KTM: 0/20
KTMF:
0/20
KTM: 0/20
KTMF:
0/20
KTM: 0/20
KTMF:
0/20
Gonzalez
1988
Butorphanol (9 participants; 12 VOC episodes): IM bu-
torphanol 2 mg, repeated within 30–60 min until pain re-
lief obtained, repeat every 2–4 hr, until discharge.
Morphine (9 participants; 12 VOC episodes): IM mor-
phine 6 mg, repeat within 30–60 min until pain relief ob-
tained, repeated every 2–4 hr, until discharge
Butorphanol:
4/12 (nausea and
vomiting)
Morphine: 4/12
(nausea and
vomiting)
Butor-
phanol:
0/12
Morphine:
0/12
Butor-
phanol:
no data
Morphine:
no data
Butor-
phanol:
no data
Morphine:
no data
Perlin
1994
Ketorolac (10 participants; 10 VOC episodes): bolus ke-
torolac 30 mg; continuous IV infusion ketorolac 120 mg, 5
mg/hr, total dose 150 mg (on first day), maximum 120 mg/
day, up to 5 days
Placebo (11 participants; 11 VOC episodes): bolus
saline; continuous IV infusion saline, up to 5 days
Ketorolac: un-
clear
Placebo: unclear
Ketorolac:
0/10
Placebo:
0/11
Ketorolac:
1/10
Placebo:
0/11
Ketorolac:
0/10
Placebo:
0/11
Qari 2007 Tinzaparin (127 participants; 127 VOC episodes): sub-
cutaneous tinzaparin 175 IU/kg, once daily, 7 days
Placebo (126 participants; 126 VOC episodes): subcuta-
neous placebo, once daily, 7 days
Tinzaparin: no
data
Placebo: no data
Tinza-
parin: no
data
Placebo:
no data
Tinza-
parin: no
data
Placebo:
no data
Tinza-
parin: no
data
Placebo:
no data
Rehmani
2013
Morphine (54 participants; 54 VOC episodes): IV mor-
phine 0.1 mg/kg, single dose
Paracetamol (52 participants; 52 VOC episodes): IV
paracetamol 1 g, single dose
Morphine: 5/54
Paracetamol:
3/52
Morphine:
0/54
Paraceta-
mol: 0/52
Morphine:
no data
Paraceta-
mol: no
data
Morphine:
no data
Paraceta-
mol: no
data
Wright
1992
Ketorolac (12 VOC episodes): IM ketorolac 60 mg, single
dose
Placebo (12 VOC episodes): IM saline, single dose
Ketorolac: 0/12
Placebo: 0/12
Ketorolac:
0/12
Placebo:
0/12
Ketorolac:
0/12
Placebo:
0/12
Ketorolac:
0/12
Placebo:
0/12
CPS: categorical pain scale; hr: hour; IM: intramuscular; IQR: interquartile range; IV: intravenous; KTM: ketorolac + tramadol + meto-
clopramide; KTMF: ketorolac + tramadol + metoclopramide + fentanyl;VAS: visual analogue scale; VCS: visual categorical score; VOC:
vaso-occlusive crisis; VRS: verbal rating scale.
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W H A T ' S   N E W
 
Date Event Description
18 February 2020 Amended Clarification added to Declarations of interest.
22 November 2019 Review declared as stable See Published notes.
 
H I S T O R Y
Protocol first published: Issue 5, 2016
Review first published: Issue 11, 2019
 
Date Event Description
18 July 2017 Amended Contact details updated.
 
C O N T R I B U T I O N S   O F   A U T H O R S
TC registered the title.
TC, IH, SB and PW wrote the 2016 protocol.
TC, IH, SB, PW and BJ screened, extracted, analysed and graded the data, and wrote the full review.
TC will be responsible for updates.
D E C L A R A T I O N S   O F   I N T E R E S T
TC: none known.
IH: none known.
SB is an internist specializing in basic and clinical haematology with an emphasis on the management of adult and children with sickle cell
disease and pain. SB has been in the Speakers Bureau of Novartis with an emphasis on Deferasirox (both Exjade and Jadenu formulations)
in September 2016.
BJ: none known.
PW undertakes work for GSK under the auspices of his company Oxford Systematic Review Services. The work is related to over-the-counter
analgesics.
The protocol for this review was identified in a 2019 audit as not meeting the current definition of the Cochrane Commercial Sponsorship
policy. At the time of its publication it was compliant with the interpretation of the existing policy. A new author team fully compliant with
the 2014 policy completed the review. As with all reviews, new and updated, at update this review will be revised according to 2020 policy
update.
S O U R C E S   O F   S U P P O R T
Internal sources
• Oxford Pain Relief Trust, UK.
External sources
• No sources of support supplied
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Types of participants: in the protocol, for any studies we identified that included participants aged 17 years and under, we planned to
extract the data on participants aged 18 years and above and to contact the study authors for the separate adult data if necessary. We
changed this approach to include the study and data on all its participants if less than 20% of the participants were aged 17 years or under.
The reason for this change was because we felt that less than 20% would not make a significant impact on the results.
If greater than 20% of the participants were aged 17 years or under, we planned to extract the data on the participants aged 18 years and
above, and contact the authors of the studies for separate adult data if necessary.
Outcomes planned: in the protocol, we expressed that death would be sought as a secondary outcome. This was not the intention and
we have not investigated it as an outcome. The implication is that the outcome, 'serious adverse events' includes death. This has been
amended in the 'Methods' section.
Risk of bias domains: in the protocol, we unintentionally omitted three domains (blinding of participants and personnel, selective
reporting bias, other). These are now outlined in the 'Methods' section.
GRADE quality of the evidence: we unintentionally omitted a final reason for downgrading to very low quality in one step (by three levels).
This is now outlined in the 'Methods' section.
Measures of treatment e=ect: we clarified that we planned not to use continuous data for our primary outcomes measuring pain. For our
secondary outcomes, we used continuous data for the meta-analysis where appropriate.
N O T E S
The research area is not active and we do not expect new RCTs to be published. Therefore, this review has now been stabilised following
discussion with the authors and editors. The review will be assessed for updating in five years. If appropriate, we will update the review
before this date if new evidence likely to change the conclusions is published, or if standards change substantially which necessitate major
revisions.
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